~~UNITED STATES~~

~~SECURITIES~~UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington,~~Washington, D.C. 20549

~~FORM~~FORM 10-Q

~~[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly periodended June 30, ~~2020~~2021

~~[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to _____

~~For the transition period from ______ to _____~~

Commission File Number: 001-36833

~~VOLITIONRX LIMITED~~

~~(Exact name of registrant as specified in its charter)~~

VOLITIONRX LIMITED

(Exact name of registrant as specified in its charter)

Delaware

91-1949078

(State or other jurisdiction of incorporation

or organization)

~~91-1949078~~(I.R.S. Employer

~~(I.R.S. Employer~~

Identification No.)

13215 Bee Cave Parkway

Suite 125, Galleria Oaks B

Austin, Texas 78738

(Address of principal executive offices)

+1 (646) ~~650–1351~~650-1351

(~~Registrant’s~~Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on ~~which~~Which

Registered

Common Stock, par value $0.001 per share

VNRX

NYSE American, LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ~~[X]~~☒ Yes ~~[ ]No~~ ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ~~[X]~~☒ Yes ~~[ ]No~~☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of ~~“large~~"large accelerated filer,~~” “accelerated~~" "accelerated filer,~~” “smaller~~" "smaller reporting company,”" and ~~“emerging~~"emerging growth ~~company”~~company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	~~[ ]~~	☐	Accelerated filer	~~[ ]~~☐
Non-accelerated filer	~~[X]~~	☒	Smaller reporting company	~~[X]~~☒
			Emerging growth company	~~[ ]~~☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ~~[ ]~~☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ~~[ ]Yes [X]~~☐ Yes ☒ No

As of August ~~6, 2020,~~5, 2021, there were ~~47,920,377~~53,145,239 shares of the ~~registrant’s~~registrant's $0.001 par value common stock issued and outstanding.

~~VOLITIONRX LIMITED~~

~~QUARTERLY REPORT~~VOLITIONRX LIMITED

QUARTERLYREPORT ON FORM 10-Q

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, ~~2020~~2021

~~TABLE~~TABLE OF CONTENTS

PART I	FINANCIAL INFORMATION	~~PAGE~~
~~Item 1.~~PAGE	~~FINANCIAL STATEMENTS (UNAUDITED)~~	3
~~Item 2.~~	~~MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS~~	22
~~Item 3.~~	~~QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK~~	30
~~Item 4.~~	~~CONTROLS AND PROCEDURES~~	30
~~PART II~~	~~OTHER INFORMATION~~
~~Item 1.~~	~~LEGAL PROCEEDINGS~~	32
~~Item 1A.~~	~~RISK FACTORS~~	32
~~Item 2.~~	~~UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS~~	32
~~Item 3.~~	~~DEFAULTS UPON SENIOR SECURITIES~~	32
~~Item 4.~~	~~MINE SAFETY DISCLOSURES~~	32
~~Item 5.~~	~~OTHER INFORMATION~~	32
~~Item 6.~~	~~EXHIBITS~~	33
~~SIGNATURES~~		34

Item 1.	FINANCIAL STATEMENTS (UNAUDITED)	4
Item 2.	MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	26
Item 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	34
Item 4.	CONTROLS AND PROCEDURES	34

PART II	OTHER INFORMATION

Item 1.	LEGAL PROCEEDINGS	35
Item 1A.	RISK FACTORS	35
Item 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	35
Item 3.	DEFAULTS UPON SENIOR SECURITIES	35
Item 4.	MINE SAFETY DISCLOSURES	35
Item 5.	OTHER INFORMATION	35
Item 6.	EXHIBITS	36

SIGNATURES		37

~~Use~~Use of Terms

Except as otherwise indicated by the context, references in this Quarterly Report on Form 10-Q to ~~“Company,” “VolitionRx,” “Volition,” “we,” “us,”~~the "Company," "VolitionRx," "Volition," "we," "us," and ~~“our”~~"our" are references to VolitionRx Limited and its wholly-owned subsidiaries, Singapore Volition Pte. Limited, Belgian Volition ~~SPRL,~~SRL, Volition Diagnostics UK Limited, Volition America, Inc., Volition Germany GmbH, and its majority-owned subsidiary Volition Veterinary Diagnostics Development LLC. Additionally, unless otherwise specified, all references to ~~“$”~~"$" refer to the legal currency of the United States of America.

Nucleosomics^TM and Nu.Q^TM® and their respective logos are trademarks and/or service marks of VolitionRx and its subsidiaries. All other trademarks, service marks and trade names referred to ~~in this Report~~herein are the property of their respective owners.

~~PART I FINANCIAL INFORMATION~~

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

ITEM 1. ~~FINANCIAL STATEMENTS (UNAUDITED)~~This Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021, or this Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this Report or incorporated by reference into this Report are forward-looking statements. These statements include, among other things, any predictions of earnings, revenues, expenses or other financial items; plans or expectations with respect to our development activities or business strategy; statements concerning clinical studies and results; statements concerning industry trends; statements regarding anticipated demand for our products, or the products of our competitors; statements relating to manufacturing forecasts, and the potential impact of our relationship with contract manufacturers and original equipment manufacturers on our business; statements relating to the commercialization of our products, assumptions regarding the future cost and potential benefits of our research and development efforts; forecasts of our liquidity position or available cash resources; statements relating to the impact of pending litigation; statements regarding the anticipated impact of the COVID-19 pandemic and statements relating to the assumptions underlying any of the foregoing. Throughout this Report, we have attempted to identify forward-looking statements by using words such as "may," "believe," "will," "could," "project," "anticipate," "expect," "estimate," "should," "continue," "potential," "plan," "forecasts," "goal," "seek," "intend," other forms of these words or similar words or expressions or the negative thereof (although not all forward-looking statements contain these words).

	·	the COVID-19 pandemic;
	·	our failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the veterinary or clinical in-vitro diagnostics, or IVD, market;
	·	a failure by the marketplace to accept the products in our development pipeline or any other diagnostic products we might develop;
	·	our failure to secure adequate intellectual property protection;
	·	the potential obsolescence of our intended products due to the highly competitive nature of the diagnostics market and its rapid technological change; and
	·	other risks identified elsewhere in this Report, as well as in our other filings with the Securities and Exchange Commission, or the SEC.

In addition, actual results may differ as a result of additional risks and uncertainties of which we are currently unaware or which we do not currently view as material to our business. For these reasons, readers are cautioned not to place undue reliance on any forward-looking statements. Our actual financial condition and results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed in the sections entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as filed with the SEC on March 22, 2021, or our Annual Report, this Report, the documents that we file as exhibits to this Report and the documents that we incorporate by reference into this Report, with the understanding that our future results may be materially different from what we currently expect. The forward-looking statements we make speak only as of the date on which they are made. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations. If we do update or correct any forward-looking statements, readers should not conclude that we will make additional updates or corrections.

Table of Contents

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

		Page

Condensed Consolidated Balance Sheets	4	5
Condensed Consolidated Statements of Operations and Comprehensive Loss	5	6
Condensed Consolidated Statements of Stockholders’ Equity	6	7
Condensed Consolidated Statements of Cash Flows	7	9
Notes to the Condensed Consolidated Financial Statements	8
	10

Table of Contents

~~VOLITIONRX LIMITED~~

VOLITIONRX LIMITED

Condensed Consolidated Balance Sheets

(Expressed in United States Dollars, except share numbers)

	June 30,		December 31,
	2021		2020
	$		$
ASSETS	(UNAUDITED)

Current Assets
Cash and cash equivalents		27,913,169		19,444,737
Accounts receivable		15,832		7,118
Prepaid expenses		935,498		303,178
Other current assets		527,827		576,660
Total Current Assets		29,392,326		20,331,693

Property and equipment, net		5,266,646		5,171,134
Operating lease right-of-use assets		318,393		326,085
Intangible assets, net		266,586		321,641
Total Assets		35,243,951		26,150,553

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities
Accounts payable		1,083,214		1,539,547
Accrued liabilities		3,152,019		3,491,740
Management and directors' fees payable		91,695		55,174
Current portion of long-term debt		822,369		841,319
Current portion of finance lease liabilities		55,335		59,930
Current portion of operating lease liabilities		157,911		179,624
Current portion of grant repayable		35,554		69,218
Total Current Liabilities		5,398,097		6,236,552

Long-term debt, net of current portion		2,219,748		2,606,885
Finance lease liabilities, net of current portion		557,338		601,967
Operating lease liabilities, net of current portion		166,085		151,828
Grant repayable, net of current portion		273,138		259,603
Total Liabilities		8,614,406		9,856,835

STOCKHOLDERS' EQUITY

Common Stock
Authorized: 100,000,000 shares of common stock, at $0.001 par value
Issued and outstanding: 53,144,082 shares and 48,607,017 shares, respectively		53,144		48,607
Additional paid-in capital		148,468,001		126,526,239
Accumulated other comprehensive income (loss)		29,607		(59,978)
Accumulated deficit		(121,817,065)		(110,173,971)
Total VolitionRx Limited Stockholders' Equity		26,733,687		16,340,897
Non-controlling interest		(104,142)		(47,179)
Total Stockholders' Equity		26,629,545		16,293,718

Total Liabilities and Stockholders' Equity		35,243,951		26,150,553

(The accompanying notes are an integral part of these condensed consolidated financial statements)

Table of Contents

VOLITIONRX LIMITED

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(Expressed in United States Dollars, except share numbers)

June 30,

December 31,

2020

2019

$

$
ASSETS
(UNAUDITED)

Current Assets

Cash and cash equivalents
21,305,266

16,966,168
Accounts receivable
3,223

-
Prepaid expenses
585,313

267,518
Other current assets
525,013

322,593
Total Current Assets
22,418,815

17,556,279

Property and equipment, net
3,265,025

2,981,225
Operating lease right-of-use assets
234,095

381,483
Intangible assets, net
328,703

372,305
Total Assets
26,246,638

21,291,292

LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities

Accounts payable
1,414,266

627,253
Accrued liabilities
2,333,253

2,168,588
Management and directors’ fees payable
10,499

21,979
Current portion of long-term debt
692,715

647,569
Current portion of finance lease liabilities
54,276

97,946
Current portion of operating lease liabilities
163,516

257,244
Current portion of grant repayable
39,321

39,295
Total Current Liabilities
4,707,846

3,859,874

Long-term debt, net of current portion
1,914,207

2,195,278
Finance lease liabilities, net of current portion
580,787

607,708
Operating lease liabilities, net of current portion
78,495

131,875
Grant repayable, net of current portion
302,106

297,991
Total Liabilities
7,583,441

7,092,726

STOCKHOLDERS’ EQUITY

Common Stock

Authorized: 100,000,000 shares of common stock, at $0.001 par value

Issued and outstanding: 46,659,554 shares and 41,125,303 shares, respectively
46,660

41,125
Additional paid-in capital
118,915,549

103,853,627
Accumulated other comprehensive income
425,276

125,670
Accumulated deficit
(100,708,942)

(89,821,856)
Total VolitionRx Limited Stockholders' Equity
18,678,543

14,198,566
Non-controlling interest
(15,346)

-
Total Stockholders’ Equity
18,663,197

14,198,566

Total Liabilities and Stockholders’ Equity
26,246,638

21,291,292

(The accompanying notes are an integral part of these condensed consolidated financial statements)

	Three Months Ended June 30,				Six Months Ended June 30,
	2021		2020		2021		2020
	$		$		$		$
Revenues
Royalty		0		1,872		0		2,112
Product		24,782		3,322		50,312		3,626
Total Revenues		24,782		5,194		50,312		5,738

Operating Expenses
Research and development		3,649,469		3,492,845		7,522,547		7,387,811
General and administrative		1,816,599		1,508,836		3,626,759		3,212,358
Sales and marketing		459,371		215,891		886,772		489,845
Total Operating Expenses		5,925,439		5,217,572		12,036,078		11,090,014

Operating Loss		(5,900,657)		(5,212,378)		(11,985,766)		(11,084,276)

Other Income (Expenses)
Grant income		391,532		90,946		391,532		98,870
(Loss) / Gain on disposal of fixed assets		(26,166)		93,202		(26,167)		93,202
Interest income		492		7,741		2,213		46,155
Interest expense		(39,688)		(22,604)		(81,869)		(56,383)

Total Other Income (Expenses)		326,170		169,285		285,709		181,844

Net Loss		(5,574,487)		(5,043,093)		(11,700,057)		(10,902,432)
Net Loss attributable to Non-Controlling Interest		47,539		5,779		56,963		15,346
Net Loss attributable to VolitionRx Limited Stockholders		(5,526,948)		(5,037,314)		(11,643,094)		(10,887,086)

Other Comprehensive Income (Loss)
Foreign currency translation adjustments		(44,548)		(74,320)		89,585		299,606
Net Comprehensive Loss		(5,619,035)		(5,117,413)		(11,610,472)		(10,602,826)

Net Loss Per Share - Basic and Diluted attributable to VolitionRx Limited		(0.10)		(0.12)		(0.22)		(0.26)

Weighted Average Shares Outstanding
- Basic and Diluted		52,947,173		43,414,318		51,943,534		42,312,172

~~VOLITIONRX LIMITED~~

~~Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)~~

~~(Expressed in United States Dollars, except share numbers)~~

Three Months ended June 30,

Six Months ended June 30,
2020

2019

2020

2019
$

$

$

$

Revenues

Royalty
1,872

-

2,112

-
Product
3,322

-

3,626

-
Total Revenues
5,194

-

5,738

-

Operating Expenses

Research and development
3,492,845

2,478,930

7,387,811

4,953,489
General and administrative
1,508,836

1,436,461

3,212,358

2,665,901
Sales and marketing
215,891

238,124

489,845

522,404
Total Operating Expenses
5,217,572

4,153,515

11,090,014

8,141,794

Operating Loss
(5,212,378)

(4,153,515)

(11,084,276)

(8,141,794)

Other Income (Expenses)

   Grant income
90,946

-

98,870

-
   Gain on disposal of fixed assets
93,202

-

93,202

-
   Interest income
7,741

29,459

46,155

41,023
   Interest expense
(22,604)

(33,115)

(56,383)

(63,216)
   Other expenses
-

-

-

(196,957)
Total Other Income (Expenses)
169,285

(3,656)

181,844

(219,150)

Provision for Income Taxes
-

-

-

-

Net Loss
(5,043,093)

(4,157,171)

(10,902,432)

(8,360,944)
Net Loss attributable to Non-Controlling Interest
5,779

-

15,346

-
Net Loss attributable to VolitionRx Limited Stockholders
(5,037,314)

(4,157,171)

(10,887,086)

(8,360,944)

Other Comprehensive Income (Loss)

Foreign currency translation adjustments
(74,320)

49,913

299,606

25,859

Net Comprehensive Loss
(5,117,413)

(4,107,258)

(10,602,826)

(8,335,085)

Net Loss Per Share – Basic and Diluted attributable to VolitionRx Limited
(0.12)

(0.11)

(0.26)

(0.22)

Weighted Average Shares Outstanding

– Basic and Diluted
43,414,318

38,876,262

42,312,172

37,266,356

(The accompanying notes are an integral part of these condensed consolidated financial statements)

~~VOLITIONRX LIMITED~~

~~Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)~~

~~(Expressed in United States Dollars, except share numbers)~~

~~For the Three and Six Months ended June 30, 2020 and June 30, 2019~~

Accumulated

Additional
Other

Non

Common Stock
Paid-in
Comprehensive
Accumulated
Controlling

Shares
Amount
Capital
Income (Loss)
Deficit
Interest
Total
#
$
$
$
$
$
$
Balance, December 31, 2019
41,125,303
41,125
103,853,627
125,670
(89,821,856)
-
14,198,566

Common stock issued for Director compensation in Volition Germany
73,263
73
333,896
-
-
-
333,969
Common stock issued for cashless exercise of stock options
19,430
20
(20)
-
-
-
-
Stock-based compensation

-
192,669
-
-
-
192,669
Stock repurchase
(11,364)
(11)
(54,423)
-
-
-
(54,434)
Foreign currency translation
-
-
-
373,926
-
-
373,926
Net loss for the period
-
-
-
-
(5,849,772)
(9,567)
(5,859,339)
Balance, March 31, 2020
41,206,632
41,207
104,325,749
499,596
(95,671,628)
(9,567)
9,185,357

Common stock issued for cash, net
5,452,922
5,453
14,229,160
-
-
-
14,234,613
Stock-based compensation
-
-
360,640
-
-
-
360,640
Foreign currency translation
-
-
-
(74,320)
-
-
(74,320)
Net loss for the period
-
-
-
-
(5,037,314)
(5,779)
(5,043,093)
Balance, June 30, 2020
46,659,554
46,660
118,915,549
425,276
(100,708,942)
(15,346)
18,663,197

Accumulated

Additional
Other

Non

Common Stock
Paid-in
Comprehensive
Accumulated
Controlling

Shares
Amount
Capital
Income (Loss)
Deficit
Interest
Total
#
$
$
$
$
$
$
Balance, December 31, 2018
35,335,378
35,335
85,604,271
223,651
(73,722,801)
-
12,140,456
Common stock issued for cash
2,478,613
2,479
6,658,192
-
-
-
6,660,671
Stock-based compensation
-
-
340,458
-
-
-
340,458
Modification of financing warrants
-
-
196,957
-
-
-
196,957
Foreign currency translation
-
-
-
(24,054)
-
-
(24,054)
Net loss for the period
-
-
-
-
(4,203,773)
-
(4,203,773)
Balance, March 31, 2019
37,813,991
37,814
92,799,878
199,597
(77,926,574)
-
15,110,715

Common stock issued for cash
1,666,667
1,667
4,998,334
-
-
-
5,000,001
Stock-based compensation
-
-
379,507
-
-
-
379,507
Foreign currency translation
-
-
-
49,913
-
-
49,913
Net loss for the period
-
-
-
-
(4,157,171)
-
(4,157,171)
Balance, June 30, 2019
39,480,658
39,481
98,177,719
249,510
(82,083,745)
-
16,382,965

(The accompanying notes are an integral part of these condensed consolidated financial statements)

Table of Contents

VOLITIONRX LIMITED

Condensed Consolidated Statements of Stockholders' Equity (Unaudited)

(Expressed in United States Dollars, except share numbers)

							Accumulated
					Additional		Other				Non
	Common Stock				Paid-in		Comprehensive		Accumulated		Controlling
	Shares		Amount		Capital		Income (Loss)		Deficit		Interest		Total
	#		$		$		$		$		$		$
Balance, December 31, 2020		48,607,017		48,607		126,526,239		(59,978)		(110,173,971)		(47,179)		16,293,718

Common stock issued for cash		4,183,533		4,184		20,324,744		0		0		0		20,328,928
Common stock issued for cashless exercise of stock options and settlement of RSUs		80,451		80		(80)		0		0		0		0
Stock-based compensation		-		0		555,342		0		0		0		555,342
Tax withholdings paid related to stock-based compensation		-		0		(23,758)		0		0		0		(23,758)
Foreign currency translation		-		0		0		134,133		0		0		134,133
Net loss for the period		-		0		0		0		(6,116,146)		(9,424)		(6,125,570)

Balance, March 31, 2021		52,871,001		52,871		147,382,487		74,155		(116,290,117)		(56,603)		31,162,793

Common stock issued for cash		251,369		251		854,460		0		0		0		854,711
Common stock issued for cashless exercise of stock options and settlement of RSUs		21,712		22		(22)		0		0		0		0
Stock-based compensation		-		0		337,744		0		0		0		337,744
Tax withholdings paid related to stock-based compensation		-		0		(106,668)		0		0		0		(106,668)
Foreign currency translation		-		0		0		(44,548)		0		0		(44,548)
Net loss for the period		-		0		0		0		(5,526,948)		(47,539)		(5,574,487)

Balance, June 30, 2021		53,144,082		53,144		148,468,001		29,607		(121,817,065)		(104,142)		26,629,545

(The accompanying notes are an integral part of these condensed consolidated financial statements)

Table of Contents

VOLITIONRX LIMITED

Condensed Consolidated Statements of Stockholders' Equity (Unaudited)

(Expressed in United States Dollars, except share numbers)

							Accumulated
					Additional		Other				Non
	Common Stock				Paid-in		Comprehensive		Accumulated		Controlling
	Shares		Amount		Capital		Income (Loss)		Deficit		Interest		Total
	#		$		$		$		$		$		$
Balance, December 31, 2019		41,125,303		41,125		103,853,627		125,670		(89,821,856)		0		14,198,566
Common stock issued for Director compensation in Volition Germany		73,263		73		333,896		0		0		0		333,969
Common stock issued for cashless exercise of stock options		19,430		20		(20)		0		0		0		0
Stock-based compensation		-		0		192,669		0		0		0		192,669
Stock repurchase		(11,364)		(11)		(54,423)		0		0		0		(54,434)
Foreign currency translation		-		0		0		373,926		0		0		373,926
Net loss for the period		-		0		0		0		(5,849,772)		(9,567)		(5,859,339)
Balance, March 31, 2020		41,206,632		41,207		104,325,749		499,596		(95,671,628)		(9,567)		9,185,357

Common stock issued for cash, net		5,452,922		5,453		14,229,160		0		0		0		14,234,613
Stock-based compensation		-		0		360,640		0		0		0		360,640
Foreign currency translation		-		0		0		(74,320)		0		0		(74,320)
Net loss for the period		-		0		0		0		(5,037,314)		(5,779)		(5,043,093)
Balance, June 30, 2020		46,659,554		46,660		118,915,549		425,276		(100,708,942)		(15,346)		18,663,197

(The accompanying notes are an integral part of these condensed consolidated financial statements)

Table of Contents

VOLITIONRX LIMITED

Condensed Consolidated Statements of Cash Flows (Unaudited)

(Expressed in United States Dollars)

	Six Months ended June 30,		Six Months Ended June 30,
	2020	2019	2021			2020
	$	$	$			$
Operating Activities
Net loss	(10,902,432)	(8,360,944)		(11,700,057	)		(10,902,432	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	359,233	339,277		471,754			359,233
Amortization of operating lease right-of-use assets	125,871	26,632		99,035			125,871
Gain on disposal of fixed assets	(93,202)	-
Loss (Gain) on disposal of fixed assets				26,166			(93,202	)
Stock-based compensation	553,309	719,965		893,086			553,309
Shares issued for Director compensation in Volition Germany	333,969	-
Financing costs for warrants modified	-	196,957
Common stock issued for Director compensation in Volition Germany				0			333,969
Changes in operating assets and liabilities:
Prepaid expenses	(317,795)	(294,833)		(632,320	)		(317,795	)
Accounts receivable	(3,223)	-		(8,682	)		(3,223	)
Other current assets	(109,213)	36,636		50,605			(109,213	)
Accounts payable and accrued liabilities	959,425	894,097		(630,236	)		959,425
Management and directors’ fees payable	(10,497)	44,336
Management and directors' fees payable				(36,791	)		(10,497	)
Right-of-use assets operating leases liabilities	(125,331)	(25,598)		(98,789	)		(125,331	)
Net Cash Used In Operating Activities	(9,229,886)	(6,423,475)		(11,566,229	)		(9,229,886	)

Investing Activities:
Purchases of property and equipment	(597,366)	(236,831)		(703,180	)		(597,366	)
Net Cash Used In Investing Activities	(597,366)	(236,831)		(703,180	)		(597,366	)

Financing Activities:
Net proceeds from issuances of common shares	14,234,613	11,660,672
Net proceeds from issuances of common stock				21,183,639			14,234,613
Tax withholdings paid related to stock-based compensation				(130,426	)		0
Common stock repurchased	(54,434)	-		0			(54,434	)
Proceeds from grants repayable	3,802	32,652		37,672			3,802
Proceeds from long-term debt	-	282,513		79,614			0
Payments on long-term debt	(234,172)	(147,421)		(383,782	)		(234,172	)
Payments on grants repayable				(47,830	)		0
Payments on finance lease obligations	(69,483)	(71,165)		(29,347	)		(69,483	)
Net Cash Provided By Financing Activities	13,880,326	11,757,251		20,709,540			13,880,326

Effect of foreign exchange on cash	286,024	(13,440)		28,301			286,024

Net Change in Cash	4,339,098	5,083,505		8,468,432			4,339,098

Cash and cash equivalents – Beginning of Period	16,966,168	13,427,222

Cash and cash equivalents – End of Period	21,305,266	18,510,727
Cash and cash equivalents - Beginning of Period				19,444,737			16,966,168
Cash and cash equivalents - End of Period				27,913,169			21,305,266

Supplemental Disclosures of Cash Flow Information:
Interest paid	56,383	63,216		81,869			56,383
Non-Cash Financing Activities:
Common Stock issued on cashless exercises of stock options	20	-
Common stock issued on cashless exercises of stock options				80			20
Offering costs from issuance of common stock	1,229,169	-		119,029			1,229,169

(The accompanying notes are an integral part of these condensed consolidated financial statements)

(The accompanying notes are an integral part of these condensed consolidated financial statements)

Table of Contents

~~VOLITIONRX~~

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 1 –- Basis of Presentation and Summary of Significant Accounting Policies

Basis of Presentation

The interim consolidated financial statements of VolitionRx Limited (the ~~“Company”~~"Company", "VolitionRx," "we" or "us") for the three and six months ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively, are not audited. Our consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods and, consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America (“("U.S. ~~GAAP”~~GAAP"). In the opinion of our management, the accompanying consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of our financial position as of June 30, ~~2020,~~2021, and our results of operations and cash flows for the periods ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively. The results of operations for the periods ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively, are not necessarily indicative of the results for a full-year period. These interim consolidated financial statements should be read in conjunction with the financial statements included in our Annual Report on Form 10-K for the year ended December 31, ~~2019,~~2020, which was filed with the Securities and Exchange Commission (the "SEC") on ~~February 20, 2020.~~March 22, 2021.

UseofEstimates of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of ~~long-lived~~intangible assets, ~~allowance for doubtful accounts~~ and valuations of stock-based compensation.

The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the ~~Company’s~~Company's estimates. To the extent there are material differences between the estimates and the actual results, future results of operations ~~will~~could be affected.

Princip~~les~~of~~Con~~solidationrinciples of Consolidation

The accompanying condensed consolidated financial statements for the period ended June 30, ~~2020~~2021 include the accounts of the Company and its subsidiaries. The Company has one wholly-owned subsidiary, Singapore Volition Pte. Limited (“("Singapore ~~Volition”~~Volition"). Singapore Volition has one wholly-owned subsidiary, Belgian Volition ~~SPRL (“~~SRL ("Belgian ~~Volition”~~Volition"). Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited (“("Volition ~~Diagnostics”~~Diagnostics"), Volition America, Inc. (“("Volition ~~America”~~America"), Volition Germany GmbH (“("Volition ~~Germany”~~Germany"), and its one majority-owned subsidiary Volition Veterinary Diagnostics Development LLC (“("Volition ~~Vet”~~Vet"). See Note 8(f) for more information regarding Volition Vet and Volition Germany. All intercompany balances and transactions have been eliminated in consolidation.

Cash and Cash Equivalents

For the purposes of the statements of cash flows, ~~we consider~~the Company considers interest bearing deposits with original maturity dates of three months or less to be cash equivalents. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets. As of June 30, ~~2020,~~2021, cash and cash equivalents totaled approximately ~~$21.3~~$27.9 million, of which ~~$14.7~~$20.2 million was held in an overnight money market account.

Table of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (continued)

Accounts Receivables

Trade accounts receivable are stated at the amount the Company expects to collect. Due to the nature of the accounts receivable balance, the Company believes the risk of doubtful accounts is minimal and therefore no allowance is recorded. If the financial condition of the ~~Company’s~~Company's customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. The Company may provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. As of June 30, ~~2020,~~2021, the accounts receivable balance was ~~$3,223~~$15,832 and the allowance for doubtful debts was $nil.

~~VOLITIONRX LIMITED~~

~~Notes to the Condensed Consolidated Financial Statements (Unaudited)~~

~~($ expressed in United States Dollars)~~

~~Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (continued)~~

Revenue Recognition

The Company adopted Accounting Standards Codification ~~(“ASC”~~("ASC") 606, “"Revenue from Contracts with Customers,”" effective January 1, 2019. Under ASC 606, the Company recognizes revenues when the customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. The Company recognizes revenues following the five step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) the Company satisfies the performance obligation(s).

The Company generates ~~revenue~~product revenues from the sale of its Nu.Q^® Vet Cancer Screening Test, from the sale of nucleosomes, and from the sale of Research Use Only kits pursuant to its license agreement with Active Motif, Inc. (“("Active ~~Motif”~~Motif") ~~for the sale of Research Use Only kits~~ from which the Company receives royalties. In addition, revenue is received from external third parties for ~~product sales and/or~~ services the Company performs for them in its laboratory.

Revenues, and their respective treatment for financial reporting purposes under ASC 606, are as follows:

Royalty

The Company receives royalty revenues on the net sales recognized during the period in which the revenue is earned, and the amount is determinable from the licensee. These are presented in ~~“Royalty”~~"Royalty" in the consolidated statements of operations and comprehensive loss. The Company does not have future performance obligations under this revenue stream. In accordance with ASC 606, the Company records these revenues based on estimates of the net sales that occurred during the relevant period from the licensee. The relevant period estimates of these royalties are based on preliminary gross sales data provided by Active Motif and analysis of historical gross-to-net adjustments. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known.

Product

The Company includes revenue from product sales recognized during the period in which goods are shipped to third parties, and the amount is deemed collectable from the third parties. These are presented in ~~“Product sales”~~"Product" in the consolidated statements of operations and comprehensive loss.

Table of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (continued)

Services

The Company includes revenue recognized from laboratory services performed in the ~~Company’s~~Company's laboratory on behalf of third parties in ~~“Services”~~"Services" in the consolidated statements of operations and comprehensive loss.

For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the ~~Company’s~~Company's control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.

~~VOLITIONRX LIMITED~~

~~Notes to the Condensed Consolidated Financial Statements (Unaudited)~~

~~($ expressed in United States Dollars)~~

~~Note 1 - Basis of Presentation~~Basic and ~~Summary of Significant Accounting Policies (continued)~~

B~~asic~~andDilu~~ted~~NetLossPerSh~~are~~Diluted Net Loss Per Share

The Company computes net loss per share in accordance with ASC 260, ~~“Earnings~~"Earnings Per Share,”" which requires presentation of both basic and diluted earnings per share ~~(“EPS”~~("EPS") on the face of the statement of ~~operations.~~operations and comprehensive loss. Basic EPS is computed by dividing net loss available to common stockholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of June 30, ~~2020, 5,208,752~~2021, 4,732,235 potential common shares equivalents from warrants, options, and restricted stock units ~~(“RSUs”~~("RSUs") were excluded from the diluted EPS calculations as their effect is anti-dilutive.

Reclassification

Certain amounts presented in previously issued financial statements have been reclassified to be consistent with the current period presentation. ~~In the statement of operations and comprehensive loss, the~~The Company has reclassified the prior ~~year~~period comparative amounts in the statement of ~~general and administrative expenses to interest income~~stockholders' equity and cash flows to be consistent with the current year classification.

Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect. The Company does not believe there are any other new ~~applicable~~ accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Table of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 1 - Basis of Presentation and Summary of Significant Accounting Policies (continued)

COVID-19 Pandemic Impact

~~On March 11, 2020, the World Health Organization designated the outbreak~~As of the ~~novel strain~~date of ~~coronavirus known as~~this filing, there continue to be widespread concerns regarding the ongoing impacts and disruptions caused by the COVID-19 aspandemic in the regions in which the Company operates. As a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work. Uncertainty with respect to the economic impactsresult of the COVID-19 pandemic, the Company has ~~introduced significant volatility~~experienced and may continue to experience disruptions that could impact our clinical trials, including delays enrolling patients and in sample collection.

The extent to which the COVID-19 pandemic will impact the Company's business, financial ~~markets. The Company did not observe significant impacts on its business or~~condition, and results of operations ~~for~~in the ~~three~~future is highly uncertain and ~~six months ended June 30, 2020 due to~~will be affected by a number of factors. These include the ~~global emergence~~duration and extent of ~~COVID-19. While~~ the ~~extent to which~~ COVID-19 ~~impacts~~pandemic, the ~~Company’s future results will depend on future developments,~~development of new variants of the ~~pandemic~~COVID-19 virus that may be more contagious or virulent than previous versions, the scope of mandated or recommended containment and ~~associated economic impacts could result in a material impact to~~mitigation measures, the ~~Company’s future financial condition, results~~effect of ~~operations~~government stabilization and ~~cash flows~~.recovery efforts, and the success of vaccine distribution programs.

~~Note~~Note 2 - Going Concern

The Company's condensed consolidated financial statements are prepared using U.S. GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred losses since inception of ~~$100.7~~$121.8 million, has negative cash flows from operations, and ~~currently~~ has ~~limited~~minimal revenues, which creates substantial doubt about its ability to continue as a going concern for a period of at least one year from the date of issuance of these condensed consolidated financial statements.

The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions, financing and/or to generate revenues as may be required to sustain its operations. Management plans to address the above as needed by (a) securing additional grant funds, (b) obtaining additional financing through debt or equity transactions, (c) granting licenses to third parties in exchange for specified up-front and/or back-end payments and (d) developing and commercializing its products on an accelerated timeline. Management continues to exercise tight cost controls to conserve cash.

The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually attain profitable operations. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

Table of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 3 - Property and Equipment

The ~~Company’s~~Company's property and equipment ~~consist~~consisted of the following amounts as of June 30, ~~2020~~2021 and December 31, ~~2019:~~2020:

				June 30,						June 30,
				2020						2021
			Accumulated	Net Carrying				Accumulated		Net Carrying
		Cost	Depreciation	Value		Cost		Depreciation		Value
	Useful Life	$	$	$	Useful Life	$		$		$
Computer hardware and software	3 years	458,766	332,512	126,254	3 years		579,410		455,285		124,125
Laboratory equipment	5 years	2,310,486	1,240,777	1,069,709	5 years		3,026,194		1,271,580		1,754,614
Office furniture and equipment	5 years	226,139	135,367	90,772	5 years		297,841		193,087		104,754
Buildings	30 years	1,473,212	163,665	1,309,547	30 years		2,293,345		239,727		2,053,618
Building improvements	5-15 years	720,464	141,598	578,866	5-15 years		1,310,063		222,745		1,087,318
Land	Not amortized	89,877	-	89,877	Not amortized		142,217		0		142,217
		5,278,944	2,013,919	3,265,025			7,649,070		2,382,424		5,266,646

				December 31,						December 31,
				2019						2020
			Accumulated	Net Carrying				Accumulated		Net Carrying
		Cost	Depreciation	Value		Cost		Depreciation		Value
	Useful Life	$	$	$	Useful Life		$	$		$
Computer hardware and software	3 years	426,461	280,554	145,907	3 years		550,254		412,805		137,449
Laboratory equipment	5 years	2,052,348	1,256,637	795,711	5 years		2,586,997		1,060,153		1,526,844
Office furniture and equipment	5 years	217,545	114,242	103,303	5 years		271,656		171,247		100,409
Buildings	30 years	1,472,211	139,021	1,333,190	30 years		2,366,236		207,111		2,159,125
Building improvements	5-15 years	630,824	117,526	513,298	5-15 years		1,285,383		184,813		1,100,570
Land	Not amortized	89,816	-	89,816	Not amortized		146,737		0		146,737
		4,889,205	1,907,980	2,981,225			7,207,263		2,036,129		5,171,134

During the six-month periods ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, the Company recognized ~~$316,405~~$425,187 and ~~$322,131,~~$316,405, respectively, in depreciation expense.

~~VOLITIONRX~~

Table of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 4 - Intangible Assets

The ~~Company’s~~Company's intangible assets consist of ~~patents.~~patents, mainly acquired in the acquisition of Belgian Volition. The patents are being amortized over the ~~assets’~~assets' estimated useful lives, which range from 8 to 20 years.

			June 30,					June 30,
			2020					2021
		Accumulated	Net Carrying			Accumulated		Net Carrying
	Cost	Amortization	Value	Cost		Amortization		Value
	$	$	$	$		$		$
Patents	1,148,059	819,356	328,703		1,219,693		953,107		266,586

			December 31,					December 31,
			2019					2020
		Accumulated	Net Carrying			Accumulated		Net Carrying
	Cost	Amortization	Value	Cost		Amortization		Value
	$	$	$		$	$		$
Patents	1,147,391	775,086	372,305		1,256,064		934,423		321,641

During the six-month periods ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, the Company recognized ~~$42,828~~$46,567 and ~~$43,778,~~$42,828, respectively, in amortization expense.

The Company amortizes the patents on a straight-line basis with terms ranging from 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows:

2020 - remaining	$	44,340
2021	$	87,591
2021 - remaining			$	45,326
2022	$	87,591	$	91,015
2023	$	87,591	$	91,015
2024	$	21,590	$	39,230
2025			$	0
Total Intangible Assets	$	328,703	$	266,586

The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 Topic “"Property, Plant and ~~Equipment~~”Equipment" as of December 31, ~~2019.~~2020. The result of this review confirmed that the ongoing value of the patents was not impaired as of December 31, ~~2019.~~2020.

Note 5 - Related Party Transactions

~~See~~Refer to Note 6,Common Stock, for common stock issued to related parties and Note 7,Stock-Based Compensation, for stock options, warrants and RSUs issued to related parties. The Company has agreements with related parties for the purchase of products and consultancy services which are accrued under management and ~~directors’~~directors' fees payable (see condensed consolidated balance sheets).

~~VOLITIONRX~~

Table of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 6 - Common Stock

As of June 30, ~~2020,~~2021, the Company was authorized to issue 100 million shares of common stock par value $0.001 per share, of which ~~46,659,554~~53,144,082 and ~~41,125,303~~48,607,017 shares were issued and outstanding as of June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively.

~~Issuances Upon Warrant~~Stock Option Exercises and ~~Option Exercises~~RSU Settlements

OnFrom January ~~7, 2020, 12,500~~13, 2021 to March 19, 2021, 7,634 stock options were exercised to purchase shares of common stock at ~~$2.50~~$3.35 per share in a cashless exercise ~~and withholding of shares for taxes~~ that resulted in the issuance of ~~6,135~~948 shares of common stock.

On January ~~7, 2020, 12,500~~20, 2021, 5,000 RSUs vested and resulted in the issuance of 3,000 shares of common stock (the remaining 2,000 shares were withheld for taxes and returned as authorized shares under the 2015 Stock Incentive Plan).

On February 2, 2021, 20,000 stock options were exercised to purchase shares of common stock at ~~$3.00~~$3.80 per share in a cashless exercise ~~and withholding of shares for taxes~~ that resulted in the issuance of ~~4,862~~6,181 shares of common stock.

On ~~January 7, 2020, 35,000~~February 8, 2021, 100,000 stock options were exercised to purchase shares of common stock at $5.00 per share in a cashless exercise that resulted in the issuance of 19,446 shares of common stock.

From February 8, 2021 to February 9, 2021, 100,000 stock options were exercised to purchase shares of common stock at $4.00 per share in a cashless ~~exercise and withholding of shares for taxes~~exercises that resulted in the issuance of ~~6,486~~32,126 shares of common stock.

On ~~January 9, 2020, 73,263 shares were issued as fully paid shares of common stock valued at $333,969 as compensation to a managing director of Volition Germany (see Note 8(f)).~~

~~From~~ February ~~24, 2020 to March 20, 2020, 8,882~~8, 2021, 50,000 stock options were exercised to purchase shares of common stock at ~~$2.35~~$3.25 per share in a cashless ~~exercises and withholding of shares for taxes~~exercise that resulted in the issuance of ~~1,947~~18,750 shares of common stock.

On April 13, 2021, 26,250 RSUs vested and resulted in the issuance of 21,712 shares of common stock (the remaining 4,538 shares were withheld for taxes and returned as authorized shares under the 2015 Stock ~~Repurchase~~Incentive Plan).

EquityCapital Raise

On January 12, 2020, the Company purchased from its Chief Medical Officer 11,364 shares of our common stock at $4.79 per share, for a total cost to the Company of $54,434. These shares were subsequently retired.

~~Equity Capital Raise~~

~~On May 20, 2020,~~February 10, 2021, the Company entered into an underwriting agreement (the "Underwriting Agreement") with ~~National Securities Corporation, acting on its own behalf and as representative of the several underwriters,~~Cantor Fitzgerald & Co. (the "Underwriter") in connection with ~~the~~an underwritten public offering ~~issuance and sale by the Company~~ of ~~4,365,000~~3,809,524 shares (the "Firm Shares") of the ~~Company’s~~Company's common stock at the public offering price of $2.75 per share, less underwriting discounts and commissions. Under the terms of the agreement, the Company granted the underwriters an option, exercisable for 30 days from the date of the agreement, to purchase up to 654,750 additional shares of the Company’s common stock to cover overallotments, if any, at the public offering price of $2.75 per share, less underwriting discounts and commissions. On May 21, 2020, the underwriters exercised the overallotment option in full. As a result of the equity capital raise, the Company issued a total of approximately 5 million shares for aggregate gross proceeds of $13.8 million. Additionally, in connection with this transaction, $1.1 million was incurred in fees relatingpursuant to the ~~equity offering, resulting in net proceeds of $12.7 million.~~

~~Equity Distribution Agreement~~

On September 7, 2018, the Company entered into an equity distribution agreement (as amended, the “Equity Distribution Agreement”) with Oppenheimer & Co. Inc. (“Oppenheimer”), which agreement allows it to offer and sell shares of common stock having an aggregate offering price of up to $10.0 million from time-to-time pursuant to aCompany's shelf registration statement on Form S-3 (declared effective by the SEC on September 28, 2018, File ~~No.333-227248)~~No. 333-227248). The Underwriter purchased the Firm Shares from the Company at a price of $4.9533 per share on February 12, 2021. The net proceeds received by the Company for the sale and issuance of the Firm Shares were approximately $18.9 million. Under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for 30 days, to purchase up to an additional 571,428 shares of Common Stock at the same price per share as the Firm Shares which option was not exercised.

EquityDistribution Agreements

On November 10, 2020, the Company entered into an equity distribution agreement (the "2020 EDA") with Cantor Fitzgerald & Co. ("Cantor") and Oppenheimer & Co. Inc. ("Oppenheimer"), to sell shares of its common stock having an aggregate offering price of up to $25.0 million from time-to-time, through an "at the market offering program" pursuant to the Company's effective "shelf" registration statement on Form S-3 (File No. 333-227248) and related prospectuses, through Cantor and Oppenheimer each acting as the ~~Company’s~~Company's agent and/or principal. ~~Through~~The Company is not obligated to sell any shares under the 2020 EDA. During the three months ended June 30, ~~2020,~~2021, the Company raised aggregate net proceeds (net of ~~approximately $1.7 million~~broker's commissions and fees) of $857,211 under the ~~Equity Distribution Agreement~~2020 EDA through the sale of ~~436,372~~251,369 shares of its common stock.

~~During the six-month period ended~~ From inception through June 30, ~~2020,~~2021, the Company raised aggregate net proceeds (net of ~~approximately $1.7 million~~broker's commissions and fees) of $1,201,167 under the ~~Equity Distribution Agreement~~2020 EDA through the sale of ~~433,172~~316,769 shares of its common stock. Additionally, in connection with this transaction, $104,813 was incurred in fees relating to the Equity Distribution Agreement. See Note 9 for details regarding additional sales of common stock under the Equity Distribution Agreement after June 30, 2020.

~~VOLITIONRX~~

Table of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note ~~7 – Stock-based Compensation~~6 - Common Stock (continued)

a)On September 7, 2018, the Company entered into an equity distribution agreement (as amended, the "2018 EDA") with Oppenheimer to sell shares of common stock having an aggregate offering price of up to $10.0 million from time-to-time, through an "at the market offering program" pursuant to the Company's effective "shelf" registration statement on Form S-3 (File No 333-227248) and related prospectuses, through Oppenheimer acting as the Company's agent and/or principal. From inception through March 31, 2021, the Company raised aggregate net proceeds (net of broker's commissions and fees) of approximately $9.7 million under the 2018 EDA through the sale of 2,539,606 shares of its common stock and fully utilized the availability under the 2018 EDA during the quarter ended March 31, 2021. No further sales will be made under the 2018 EDA.

Note 7 - Stock-Based Compensation

a) Warrants

The following table summarizes the changes in warrants outstanding of the Company during the six-month period ended June 30, ~~2020:~~2021:

Weighted

Number of

Average

Warrants

Exercise Price ($)
Outstanding at December 31, 2019
190,000

2.90
Granted
50,000

3.45
Exercised
-

-
Expired
-

-
Outstanding at June 30, 2020
240,000

3.02

Exercisable at June 30, 2020
190,000

2.90

	Number of	Weighted Average
	Warrants	Exercise Price ($)
Outstanding at December 31, 2020	175,000		2.75
Granted	310,000		4.52
Outstanding at June 30, 2021	485,000		3.88

Exercisable at June 30, 2021	125,000		2.47

Effective February 26, 2020, the vesting criteria of the remaining installment of a warrant originally granted March 20, 2013 to an officer of the Company, and previously amended, was deemed met pursuant to the approval of the Compensation Committee, resulting in the vesting of the Warrant as to 125,000 shares effective February 26, 2020, with an expiration date of February 26, 2023.

~~Effective March~~January 1, ~~2020,~~2021, the Company granted warrants to purchase ~~50,000~~125,000 shares of common stock to a Company employee for services to the Company. These warrants vest on ~~September~~January 1, ~~2021~~2022 (subject to continued employment through such date) and expire on ~~March~~January 1, ~~2026,~~2027, with an exercise price of ~~$3.45~~$3.95 per share. The Company has calculated the estimated fair market value of these warrants at ~~$86,771,~~$242,877, using the Black-Scholes model and the following assumptions: term ~~3.75~~3.5 years, stock price ~~$3.44,~~$3.95, exercise price ~~$3.45, 69.03%~~$3.80, 74.53% volatility, ~~0.95%~~0.50% risk free rate, and no forfeiture rate.

Effective February 1, 2021, the Company granted warrants to purchase 185,000 shares of common stock to a Company employee for services to the Company. These warrants vest on February 1, 2022 (subject to continued employment through such date) and expire on February 1, 2027, with an exercise price of $4.90 per share. The Company has calculated the estimated fair market value of these warrants at $459,352, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $4.90, exercise price $4.80, 75.03% volatility, 0.59% risk free rate, and no forfeiture rate.

Below is a table summarizing the warrants issued and outstanding as of June 30, ~~2020,~~2021, which have an aggregate weighted average remaining contractual life of ~~2.65~~4.46 years.

Weighted

Average

Remaining
Proceeds to
Number

Number

Exercise

Contractual
Company if
Outstanding

Exercisable

Price ($)

Life (Years)
Exercised ($)
150,000

150,000

2.47

1.44

370,500
50,000

-

3.45

5.67

172,500
40,000

40,000

4.53

0.38

181,200
240,000

190,000

724,200

				Weighted Average
				Remaining		Proceeds to
Number	Number	Exercise		Contractual		Company if
Outstanding	Exercisable		Price ($)		Life (Years)		Exercised ($)
125,000	125,000		2.47		0.83		308,750
50,000	-		3.45		4.67		172,500
185,000	-		4.90		5.59		906,500
125,000	-		3.95		5.51		493,750
485,000	125,000						1,881,500

Stock-based compensation expense related to warrants of $41,587 and $4,127 was recorded in the six months ended June 30, 2020 and June 30, 2019, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is $65,519 and is expected to be recognized over a period of 1.17 years. As of June 30, 2020, the total intrinsic value of warrants outstanding was $235,000.

Table of Contents

~~VOLITIONRX~~

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 7 ~~– Stock-based~~- Stock-Based Compensation (continued)

b)a) Warrants (continued)

Stock-based compensation expense related to warrants of $337,823 and $41,587 was recorded in the six months ended June 30, 2021 and June 30, 2020, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is $402,971 and is expected to be recognized over a period of 0.59 years. As of June 30, 2021, the total intrinsic value of warrants outstanding was $102,500.

b) Options

The following table summarizes the changes in options outstanding of the Company during the six-month period ended June 30, ~~2020:~~2021:

Number of

Weighted Average

Options

Exercise Price ($)
Outstanding at December 31, 2019

4,169,301

3.88
Granted

835,000

3.60
Exercised

(68,882)

3.33
Expired/Cancelled

(19,167)

5.00
Outstanding at June 30, 2020

4,916,252

3.84

Exercisable at June 30, 2020

4,081,252

3.89

			Weighted
			Average
	Number of		Exercise
	Options		Price ($)
Outstanding at December 31, 2020		4,278,619		4.00
Granted		40,000		3.60
Exercised		(277,634)		4.19
Outstanding at June 30, 2021		4,040,985		3.99

Exercisable at June 30, 2021		3,990,985		3.99

Effective ~~April 13, 2020,~~May 20, 2021, the Company granted stock options to purchase ~~835,000~~40,000 shares of common stock to ~~various~~a Company ~~personnel (including directors, executives, members of management and employees)~~employee in exchange for services provided to the Company. These options vest on ~~April 13, 2021~~May 20, 2022 and expire 5five years after the vesting date, with an exercise price of ~~$3.44~~$3.60 per share. The Company has calculated the estimated fair market value of these options at ~~$1,481,709,~~$73,641, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price ~~$3.52,~~$3.50, exercise price $3.60, ~~72.94%~~76.16% volatility, ~~0.54%~~0.58% risk free rate, and no forfeiture rate.

Below is a table summarizing the options issued and outstanding as of June 30, ~~2020,~~2021, all of which were issued pursuant to the 2011 Equity Incentive Plan (for option issuances prior to 2016) or the 2015 Stock Incentive Plan (for option issuances commencing in 2016) and which have an aggregate weighted average remaining contractual life of ~~3.05 years~~.2.54 years. As of June 30, ~~2020,~~ 2021, an aggregate of ~~4,250,000~~6,000,000 shares of common stock were authorized for issuance under the 2015 Stock Incentive Plan,, of which ~~261,867~~ 1,968,852 shares of common stock remained available for future issuance thereunder.

Weighted

Average

Remaining

Proceeds to
Number

Number

Exercise

Contractual

Company if
Outstanding

Exercisable

Price ($)

Life (Years)

Exercised ($)
2,717

2,717

2.35

0.18

6,385
310,000

310,000

2.50

0.13

775,000
310,000

310,000

3.00

0.13

930,000
685,000

685,000

3.25

4.62

2,226,250
17,767

17,767

3.35

0.62

59,519
835,000

-

3.60

5.79

3,006,000
20,000

20,000

3.80

0.88

76,000
1,782,837

1,782,837

4.00

2.31

7,131,348
17,768

17,768

4.35

1.62

77,291
89,163

89,163

4.38

3.57

390,534
50,000

50,000

4.80

2.51

240,000
796,000

796,000

5.00

2.74

3,980,000
4,916,252

4,081,252

18,898,327

						Weighted Average
						Remaining		Proceeds to
Number		Number		Exercise		Contractual		Company if
	Outstanding		Exercisable		Price ($)		Life (Years)		Exercised ($)
	635,000		635,000		3.25		3.62		2,063,750
	2,717		2,717		3.35		0.18		9,102
	10,000		-		3.40		5.42		34,000
	860,000		820,000		3.60		4.85		3,096,000
	1,682,837		1,682,837		4.00		1.26		6,731,348
	15,268		15,268		4.35		0.65		66,416
	89,163		89,163		4.38		2.57		390,534
	50,000		50,000		4.80		1.51		240,000
	696,000		696,000		5.00		1.74		3,480,000
	4,040,985		3,990,985						16,111,150

~~VOLITIONRX~~

Table of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 7 ~~– Stock-based~~- Stock-Based Compensation (continued)

b)Options (continued)

Stock-based compensation expense related to stock options of ~~$482,103~~$418,292 and ~~$715,838~~$482,103 was recorded in the six months ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively. Total remaining unrecognized compensation cost related to non-vested stock options is ~~$1,165,070.~~$72,095 and is expected to be recognized over a period of 0.89 years. As of June 30, ~~2020,~~2021, the total intrinsic value of stock options outstanding was ~~$1,402,929.~~$25,400.

c)c) Restricted Stock Units (RSUs)

Below is a table summarizing the RSUs issued and outstanding as of June 30, ~~2020,~~2021, all of which were issued pursuant to the 2015 Stock Incentive Plan.

	Number of	Share Price	Number of RSUs		Share Price ($)
	RSUs	($)
Outstanding at December 31, 2019	-	-
Outstanding at December 31, 2020				67,500		3.47
Granted	52,500	3.52		185,000		3.37
Vested	-	-		(31,250)		3.56
Cancelled	-	-		(15,000)		3.30
Outstanding at June 30, 2020	52,500	3.52
Outstanding at June 30, 2021				206,250		3.38

Effective ~~April 13, 2020,~~January 1, 2021, the Company granted RSUs of ~~52,500~~5,000 shares of common stock to ~~various~~a Company ~~personnel (including a director~~employee in exchange for services provided to the Company. These RSUs vested immediately, on January 1, 2021 and ~~employee)~~resulted in the issuance of 3,000 shares (the remaining 2,000 shares were withheld for taxes and returned as authorized shares under the 2015 Stock Incentive Plan) and total compensation expense of $19,450.

Effective March 25, 2021, the Company granted aggregate RSUs of 30,000 shares of common stock to two non-executive directors in exchange for services provided to the Company. These RSUs vest over 2two years, with 50% vesting on each of ~~April 13, 2021~~March 25, 2022 and ~~April 13, 2022~~March 25, 2023 and will result in total compensation expense of ~~$184,800.~~$107,700.

~~Below is~~On March 25, 2021, 15,000 RSUs previously granted to a ~~table summarizing~~non-executive director were cancelled and returned as authorized shares under the ~~RSUs issued and outstanding as~~2015 Stock Incentive Plan upon the resignation of ~~June 30, 2020 and which have an aggregate weighted average remaining contractual life of 1.29 years.~~such director prior to vesting.

Weighted

Average

Remaining
Number

Number

Share

Contractual
Outstanding

Exercisable

Price ($)

Life (Years)
52,500

-

3.52

1.29

On April 13, 2021, 26,250 RSUs vested and resulted in the issuance of 21,712 shares (the remaining 4,538 shares were withheld for taxes and returned as authorized shares under the 2015 Stock Incentive Plan).

~~Stock-based~~Effective May 1, 2021, the Company granted RSUs of 150,000 shares of common stock to an employee in exchange for services provided to the Company. These RSUs vest over three years with 50,000 units vesting on each of May 1, 2022, May 1, 2023 and May 1, 2024, respectively, and will result in total compensation expense ~~related to RSUs~~ of $29,619 and $nil was recorded in the six months ended June 30, 2020 and June 30, 2019, respectively. Total remaining unrecognized compensation cost related to non-vested RSUs is $155,181. As of June 30, 2020, the total intrinsic value of the RSUs outstanding was $19,425.$496,500

Table of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note ~~8 – Commitments and Contingencies~~7 - Stock-based Compensation (continued)

a)~~Finance Lease Obligations~~ c) Restricted Stock Units (RSUs) (continued)

~~In 2015,~~Below is a table summarizing the ~~Company entered into~~RSUs issued and outstanding as of June 30, 2021 and which have an ~~equipment finance lease~~aggregate weighted average remaining contractual life of 1.62 years.

				Weighted
				Average
				Remaining
Number		Share		Contractual
	Outstanding		Price ($)		Life (Years)
	150,000		3.31		1.84
	26,250		3.52		0.39
	30,000		3.59		1.23
	206,250

Stock-based compensation expense related to ~~purchase three Tecan machines (automated liquid handling robots) for €550,454 Euros that matured~~RSUs of $136,971 and $29,619 was recorded in ~~May 2020.~~the six months ended June 30, 2021 and June 30, 2020, respectively. Total remaining unrecognized compensation cost related to non-vested RSUs is $568,243. As of June 30, ~~2020,~~2021, the ~~balance payable~~total intrinsic value of the RSUs outstanding was $nil.

Note 8 - Commitments and Contingencies

a)Finance Lease Obligations

In 2016, the Company entered into a real estate finance lease with ING Asset Finance Belgium S.A. ~~(“ING”~~("ING") to purchase a property located in Belgium for €1.12 million, ~~Euros,~~ maturing in May ~~2031.~~2031 with implicit interest of 2.62%. As of June 30, ~~2020,~~2021, the balance payable was ~~$619,808.~~$606,213.

In 2018, the Company entered into a ~~finance~~capital lease with BNP Paribas leasing solutions to purchase a freezer for the Belgium facility for €25,000, ~~Euros,~~ maturing in January ~~2022.~~2022 with implicit interest of 1.35%. The leased equipment is amortized on a straight-line basis over 5 years. As of June 30, ~~2020,~~2021, the balance payable was ~~$15,255.~~$6,460.

The following is a schedule showing the future minimum lease payments under finance leases by years and the present value of the minimum payments as of June 30, ~~2020.~~2021.

2020 - remaining	$	34,997
2021	$	69,993
2021 - remaining			$	36,917
2022	$	61,839	$	65,234
2023	$	60,427	$	63,745
2024	$	60,426	$	63,744
2025			$	63,744
Greater than 5 years	$	445,634	$	406,356
Total	$	733,316	$	699,740
Less: Amount representing interest	$	(98,253)	$	(87,067)
Present value of minimum lease payments	$	635,063	$	612,673

Table of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 8 - Commitments and Contingencies (continued)

b)Operating Lease Right-of-Use Obligations

As all the existing leases subject to the new lease standard ASC 842 (~~“Leases”~~("Leases") were previously classified as operating leases by the Company, they were similarly classified as operating leases under the new standard. The Company has determined that the identified operating leases did not contain non-lease components and require no further allocation of the total lease cost. Additionally, the agreements in place did not contain information to determine the rate implicit in the leases, so wethe Company used ~~our~~its incremental borrowing rate as the discount rate. ~~Our~~The Company's weighted average discount rate is ~~4.47%~~4.49% and the weighted average remaining lease term is 1933 months.

As of June 30, ~~2020,~~2021, operating lease right-of-use assets and liabilities arising from operating leases were ~~$234,095~~$318,393 and ~~$242,011,~~$323,996, respectively. During the six months ended June 30, ~~2020,~~2021, cash paid for amounts included for the measurement of lease liabilities was ~~$116,541~~$44,059 and the Company recorded operating lease expense of ~~$117,357.~~$44,355.

The following is a schedule showing the future minimum lease payments under operating leases by years and the present value of the minimum payments as of June 30, ~~2020.~~2021.

2020 - remaining
$
121,708
2021
$
77,664
2022
$
34,500
2023
$
16,886
2024
$
1,056
Total Operating Lease Obligations
$
251,814
Less: Amount representing interest
$
(9,803)
Present Value of minimum lease payments
$
242,011

~~VOLITIONRX LIMITED~~

~~Notes to the Condensed Consolidated Financial Statements (Unaudited)~~

~~($ expressed in United States Dollars)~~

~~Note 8 – Commitments and Contingencies (continued)~~

b)~~Operating Lease Right-of-Use Obligations (continued)~~

2021 - remaining	$	103,130
2022	$	101,644
2023	$	76,422
2024	$	50,027
2025	$	5,417
Total Operating Lease Obligations	$	336,640
Less: Amount representing interest	$	(12,644)
Present Value of minimum lease payments	$	323,996

The ~~Company’s~~Company's office space leases are ~~short term~~short-term and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the six months ended June 30, ~~2020, $10,737~~2021, $37,417 was recognized in short-term lease costs associated with office space leases. The annual payments remaining for short-term office leases were as follows:

2020 - remaining
$
1,740
Total Operating Lease Obligations
$
1,740

2021 - remaining	$	38,855
2022	$	38,222
Total Operating Lease Liabilities	$	77,077

c)Grants Repayable

In 2010, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for €1.05 ~~million Euros.~~million. Per the terms of the agreement, €314,406 ~~Euros~~ of the grant is to be repaid, by ~~instalments~~installments over the period from June 30, 2014 to June 30, 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 ~~Euros~~ and the 6% royalty on revenue, is equal to twice the amount of funding received. As of June 30, ~~2020,~~2021, the grant balance repayable was ~~$137,519.~~$65,183.

In 2018, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for ~~€605,000 Euros.~~€605,000. Per the terms of the agreement, €181,500 ~~Euros~~ of the grant is to be repaid by ~~instalments~~installments over 12 years commencing in 2020. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 ~~Euros~~ and the 3.53% royalty on revenue, is equal to the amount of funding received. As of June 30, ~~2020,~~2021, the grant balance repayable was ~~$203,908.~~$127,215.

Table of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 8 - Commitments and Contingencies (continued)

c) Grants Repayable (continued)

In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for €929,433. Per the terms of the agreement, €278,830 of the grant is to be repaid by installments over 15 years commencing in 2022. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received. As of June 30, 2021, the grant balance repayable was $55,040.

In 2020, the Company entered into an agreement with the Walloon Region government in Belgium for a research grant for €495,000. Per the terms of the agreement, €148,500 of the grant is to be repaid by installments over 10 years commencing in 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received. As of June 30, 2021, the grant balance repayable was $61,254.

As of June 30, ~~2020,~~2021, the total grant balance repayable was ~~$341,427~~$308,692 and the payments remaining were as follows:

2020 - remaining	$	52,915
2021	$	50,001
2021 - remaining			$	0
2022	$	47,298	$	46,138
2023	$	48,468	$	44,367
2024	$	20,391	$	19,253
2025			$	21,194
Greater than 5 years	$	122,354	$	177,740
Total Grants Repayable	$	341,427	$	308,692

d)Long-Term Debt

In 2016, the Company entered into a 7-year loan agreement with Namur Invest for €440,000 ~~Euros~~ with a fixed interest rate of 4.85%, maturing in December 2023. As of June 30, ~~2020,~~2021, the principal balance payable was ~~$285,383.~~$220,175.

In 2016, the Company entered into a 15-year loan agreement with ING for €270,000 ~~Euros~~ with a fixed interest rate of 2.62%, maturing in December 2031. As of June 30, ~~2020,~~2021, the principal balance payable was ~~$243,940.~~$238,224.

In 2017, the Company entered into a 4-year loan agreement with Namur Invest for €350,000 ~~Euros~~ with a fixed interest rate of 4.00%, maturing in June 2021. As of June 30, ~~2020,~~2021, the principal balance payable was ~~$118,008.~~$0.

In 2017, the Company entered into a 7-year loan agreement with SOFINEX for up to €1 million ~~Euros~~ with a fixed interest rate of 4.50%, maturing in September 2024. As of June 30, ~~2020,~~2021, €1 million ~~Euros has~~had been drawn down under this agreement and the principal balance payable was ~~$1,067,291.~~

~~VOLITIONRX LIMITED~~

~~Notes to the Condensed Consolidated Financial Statements (Unaudited)~~

~~($ expressed in United States Dollars)~~

~~Note 8 – Commitments and Contingencies (continued)~~

d)~~Long-Term Debt (continued)~~$888,857.

In 2018, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for €500,000 ~~Euros~~ with a fixed interest rate of ~~4.00%~~4.0%, maturing in June 2022. As of June 30, ~~2020,~~2021, the principal balance payable was ~~$330,568.~~$177,839.

In 2019, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for €500,000 ~~Euros~~ with a fixed interest rate of 4.80%, maturing in September ~~2023.~~2024. As of June 30, ~~2020,~~2021, the principal balance payable was ~~$561,732.~~$553,460.

On October 13, 2020, the Company entered into a 10-year loan agreement with Namur Invest for a maximum of €830,000 with fixed interest rate of 4.00%, maturing March 2031. As of June 30, 2021, the principal balance payable was $963,562.

Table of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 8 - Commitments and Contingencies (continued)

d) Long-Term Debt (continued)

As of June 30, ~~2020,~~2021, the total balance for long-term debt payable was ~~$2,606,922~~$3,042,117 and the payments remaining were as follows:

2020 - remaining	$	479,678
2021	$	742,694
2021 - remaining			$	508,394
2022	$	623,184	$	779,595
2023	$	526,943	$	678,071
2024	$	328,193	$	527,666
2025			$	145,755
Greater than 5 years	$	180,377	$	784,900
Total	$	2,881,069	$	3,424,381
Less: Amount representing interest	$	(274,147)	$	(382,264)
Total Long-Term Debt	$	2,606,922	$	3,042,117

e) Collaborative Agreement Obligations

~~In 2015, the Company entered into a research sponsorship agreement with DKFZ in Germany for a 3-year period for €338,984 Euros. As of June 30, 2020, $84,260 is still to be paid~~ ~~by the Company under this agreement.~~

In 2016, the Company entered into a research co-operation agreement with DKFZ in Germany for a ~~5-year~~five-year period for ~~€400,000 Euros.~~€400,000. As of June 30, ~~2020, $224,693~~2021, $237,029 is still to be paid by the Company under this agreement.

~~In 2017, the Company entered into a collaborative research agreement with Munich University in Germany for a 3-year period for~~ ~~€360,000 Euros. As of June 30, 2020, $110,099 is still to be paid by the Company under this agreement.~~

~~In 2017, the Company entered into a clinical study research agreement with~~ ~~the~~ ~~University~~ ~~of Michigan for a 3-year period for~~ up to $3 million. This agreement was amended in February 2020 to redefine a new clinical study. Pursuant to the terms of the amendment, the parties acknowledged that, although not fully-completed, the requirements of the original clinical study had been satisfied, including any and all payment obligations by the Company. Further, the Amendment provided that a new clinical study would be undertaken at no additional cost to the Company. As of June 30, 2020, ~~up to $138,000 is still accrued~~ ~~by the Company for any additional expenses for the new clinical study.~~

In 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a ~~3-year~~three-year period for a cost to the Company of up to $2.55 million payable over such period. As of June 30, ~~2020, $1.28 million~~2021, $510,000 is still to be paid by the Company under this agreement.

In 2019, the Company entered into a research collaboration agreement with the University of Taiwan for a ~~2-year~~two-year period to collect a total of 1,200 samples for a cost to the Company of up to $320,000 payable over such period. As of June 30, ~~2020, $160,000~~2021, $0 is still to be paid by the Company under this agreement.

In 2019, the Company entered into a funded sponsored research agreement with the Texas A&M University ~~System (“TAMU”~~("TAMU") in consideration for the license granted to the Company for a ~~5-year~~five-year period for a cost to the Company of up to $400,000 payable over such period. As of June 30, ~~2020, $345,443~~2021, $122,123 is still to be paid by the Company under this agreement.

~~VOLITIONRX~~

On September 16, 2020, the Company entered into a research agreement for the bioinformatic analysis of cell-free DNA fragments from whole-genome sequencing with the Hebrew University of Jerusalem for six months for a cost to the Company of €54,879. Subsequently the parties entered into an amendment to the agreement with an additional cost to the Company of €155,115. As of June 30, 2021, $94,947 is still to be paid by the Company under the amended agreement.

As of June 30, 2021, the total amount to be paid for future research and collaboration commitments was approximately $964,099 and the payments remaining were as follows:

2021 - remaining	$	842,026
2022 - 2025	$	122,073
Total Collaborative Agreement Obligations	$	964,099

Table of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

Note 8 –- Commitments and Contingencies (continued)

f) Other Commitments

e) ~~Collaborative Agreement Obligations (continued)~~

In 2019, the Company entered into a lyophilization study and a CE marking project including GMP validation and documentation with Biomerica Inc. for $160,000. As of June 30, 2020, $54,663 is still to be paid by the Company under this agreement.

~~As of June 30, 2020, the total amount to be paid for future research~~ ~~and collaboration commitments was approximately $2.39 million and the annual payments remaining were as follows:~~

2020 - remaining
$
1,098,624
2021 - 2024
$
1,293,534
Total Collaborative Agreement Obligations
$
2,392,158

f)~~Other Commitments~~

Volition Vet

On August 7, 2019, the Company entered into a consulting services agreement with Novis Animal Solutions LLC, to provide chief executive officer services for Volition Vet in exchange for payment of consultancy fees and a potential equity interest of up to 5% in Volition Vet upon achievement of revenue milestones. The term of the contract is perpetual and terminable on 2 months’ written notice from either party. As of June 30, 2020, Novis Animal Solutions LLC has no equity interest in Volition Vet.

On October 25, 2019, the Company entered into an agreement with TAMU for provision of in kind services of personnel, animal samples and ~~laboratories~~laboratory equipment in exchange for a non-controlling interest of 7.5% in Volition Vet ~~and for~~with an additional 5%, vesting in a ~~further 5%, effective October 25, 2020,~~year from the date of the agreement, giving ~~them~~TAMU in ~~total~~aggregate, a 12.5% equity interest as of such date. As of June 30, ~~2020,~~2021, TAMU has a ~~7.5 %~~12.5% equity interest in Volition Vet.

Volition Germany

On January 10, 2020, the Company, through its wholly-owned subsidiary Belgian Volition, acquired an epigenetic reagent company, Octamer GmbH ~~(“Octamer”~~("Octamer"), based in Munich, Germany, and hired its founder for his expertise and knowledge to be passed to Company personnel. On March 9, 2020, Octamer was renamed to Volition Germany GmbH (or ~~“Volition Germany”~~"Volition Germany").

Upon considering the definition of a business, as defined in ASC 805 “"Business Combinations,,” " paragraph ~~805-10-20,~~805-10-20, which is an integrated set of activities and assets that is capable of being conducted and managed for the purpose of providing a return, the Company has determined that this did not constitute a business. This is primarily due to the fact that additional inputs are needed in the form of training personnel further to produce outputs. Accordingly, the Company has treated this transaction as the hiring of a member of management, ~~and acquisition of assets.~~described below, rather than accounting for the transaction as a business combination.

The Company agreed to terms of the transaction on December 13, 2019 and closed on January 10, 2020. Pursuant to the transaction agreement, the Company purchased all outstanding shares of Octamer. In exchange, the Company agreed to issue 73,263 ~~newly-issued~~newly issued restricted shares of Company common stock valued at $333,969 (based on the $4.56 per share volume weighted trading price for the five days prior to December 13, 2019), committed to pay approximately €350,000, ~~Euros~~ subject to adjustments, and agreed to pay off certain Octamer expenses leading up to the agreement (representing net liabilities of $6,535). At closing, the Company issued 73,263 restricted shares of Company common stock, paid an adjusted amount of approximately $357,000 (€~~321,736 Euros)~~321,736) and recorded a holdback liability of $55,404 (€~~50,000 Euros) to be~~50,000). During the three months ended March 31, 2021, an amount of €43,152 was paid ~~after~~in full settlement of the ~~holdback period of 9 months following the closing (subject to offset for breaches of representations and warranties).~~amount due.

In connection with the transaction agreement, the Company also entered into a ~~2-year~~two-year Managing ~~Director’s~~Director's agreement with the founder of Octamer to continue to manage Volition Germany for a payment of €288,000 ~~Euros~~ payable in equal monthly installments over such ~~2-year~~two-year period and a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of ~~Octamer’s~~Volition Germany's nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of 5five years post-closing.

~~VOLITIONRX~~

During the three months ended March 31, 2020, the Company recorded approximately $753,000 in January 2020 as compensation expense as a result of cash paid in, holdback liability, stock issued and assumption of expenses. As of June 30, 2021, $85,330 is still to be paid by the Company under the Managing Director's agreement and $229 is payable under the 6% royalty agreement.

Table of Contents

VOLITIONRX LIMITED

Notes to the Condensed Consolidated Financial Statements (Unaudited)

($ expressed in United States Dollars)

~~Note~~Note 8 –- Commitments and Contingencies (continued)

f) Other Commitments (continued)

f)~~Other Commitments (continued)~~Volition America

~~Volition Germany (continued)~~

On November 3, 2020, the Company entered into a professional services master agreement with Diagnostic Oncology CRO, LLC to conduct a pivotal clinical trial and provide regulatory submission and reimbursement related services. Under the terms of the agreement Diagnostic Oncology CRO, LLC will provide ad hoc consulting assistance on a project-by-project basis related to the review and assessment of existing data and information to prepare recommended intended use claims and coverage/reimbursement plans to support the preparation of FDA pre-submissions, clinical trial protocol development and study administration, and potential 510k regulatory marketing submissions of the Company's diagnostic tests, including those proposed for use as an adjunct diagnostic tool for common and aggressive forms of Non-Hodgkin's Lymphoma. The initial projects contemplated by the agreement relating to Non-Hodgkin's Lymphoma obligate the Company ~~recorded approximately $753,000~~to pay in ~~compensation expense~~aggregate of up to $2.9 million over a period of 22 months. Such payment obligations are on a project-by-project basis as ~~a result~~deliverables are executed and subject to certain terms and conditions. Additionally, the Company may terminate the agreement or any project with or without cause upon at least 30 days' prior written notice. Unless earlier terminated, the term of ~~cash paid, holdback liability, stock issued and assumption of expenses.~~the agreement is until December 31, 2025 or such later date as when all projects have been completed. As of June 30, ~~2020, $242,667 is still to be paid by the Company under the Managing Director’s agreement, and $88~~2021, $18,344 is payable by Company for services rendered under the ~~6% royalty~~ agreement.

g)Legal Proceedings

There are no legal proceedings which the Company believes will have a material adverse effect on its financial position.

Note 9 –- Subsequent Events

On July ~~16, 2020, 22,500 stock~~14, 2021, the Board of Directors of the Company amended the terms of certain outstanding options ~~were exercised~~granted pursuant to the 2011 Equity Incentive Plan such that (i) the expiration date for outstanding options to purchase up to an aggregate of 292,000 shares of the Company's common stock, ~~at $2.50 per share in a cashless exercise~~granted on July 23, 2015, was extended from five years and ~~withholding~~six months after vesting to ten years from the date of ~~shares~~grant, or an expiration date of July 23, 2025, (ii) the expiration date for ~~taxes that resulted in the issuance~~outstanding options to purchase up to an aggregate of ~~4,486~~6,367 shares of the Company's common ~~stock.~~

~~On July 21, 2020, 110,000~~ stock, granted on March 20, 2013, was extended from six years after vesting to ten years from the date of grant, or an expiration date of March 20, 2023, and (iii) the expiration date for outstanding options ~~were exercised~~ to purchase up to an aggregate of 8,151 shares of the Company's common stock, ~~at $2.50 per share in cashless exercises and withholding~~granted September 2, 2013, was extended from six years after vesting to ten years from the date of ~~shares for taxes that resulted in the issuance~~grant, or an expiration date of ~~21,949 shares~~September 2, 2023. As a result of ~~common stock.~~

~~On July 21, 2020, 110,000 stock~~these amendments $452,433 will be recorded as additional options ~~were exercised to purchase shares of common stock at $3.00 per share in cashless exercises and withholding of shares for taxes that resulted in the issuance of 14,380 shares of common stock.~~

On August 4, 2020, 25,000 stock options were exercised to purchase shares of common stock at $2.50 per share in a cashless exercise and withholding of shares for taxes that resulted in the issuance of 2,920 shares of common stock.

On August 4, 2020, 25,000 stock options were exercised to purchase shares of common stock at $3.00 per share in a cashless exercise and withholding of shares for taxes that resulted in the issuance of 1,529 shares of common stock.expense.

From July 1 to August ~~6, 2020,~~5, 2021, the Company raised aggregate net proceeds (net of broker's commissions and fees) of approximately ~~$4.7 million~~$3,830 under the ~~Equity Distribution Agreement~~2020 EDA through the sale of ~~approximately 1.2 million~~1,157 shares of its common ~~stock in accordance with a Rule 10b5-1 plan.~~stock.

Effective August 3, 2021, the Company granted stock options to purchase an aggregate maximum of 926,640 shares of common stock, pursuant to the 2015 Stock Incentive Plan, to various designated directors, officers and employees, with an exercise price of $3.40 per share. The actual number of options that are eligible for the time-based vesting is fixed based upon the timely achievement of certain pre-determined corporate milestones by the Company as set forth in the grant documents. The options eligible for vesting shall vest in two equal installments at 12 months and 24 months from the grant date, subject to continued service and expire 10 years from the date of grant.

Effective August 3, 2021, the Company granted RSUs for an aggregate maximum of 460,191 shares of common stock, pursuant to the 2015 Stock Incentive Plan, to various designated directors, officers and employees. The actual number of RSUs that are eligible for the time-based vesting is fixed based upon the timely achievement of certain pre-determined corporate milestones by the Company as set forth in the grant documents. The RSUs eligible for vesting shall vest in two equal installments at 12 months and 24 months from the grant date, subject to continued service.

END NOTES TO FINANCIALS

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

~~Cautionary Note Regarding Forward-Looking Statements~~

This Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020, or this Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this Report or incorporated by reference into this Report are forward-looking statements. These statements include, among other things, any predictions of earnings, revenues, expenses or other financial items; plans or expectations with respect to our development activities or business strategy; statements concerning clinical studies and results; statements concerning industry trends; statements regarding anticipated demand for our products, or the products of our competitors; statements relating to manufacturing forecasts, and the potential impact of our relationship with contract manufacturers and original equipment manufacturers on our business; statements relating to the commercialization of our products, assumptions regarding the future cost and potential benefits of our research and development efforts; forecasts of our liquidity position or available cash resources; statements relating to the impact of pending ~~litigation;~~statements regarding the anticipated impact of the COVID-19 pandemic; and statements relating to the assumptions underlying any of the foregoing. Throughout this Report, we have attempted to identify forward-looking statements by using words such as “may,” “believe,” “will,” “could,” “project,” “anticipate,” “expect,” “estimate,” “should,” “continue,” “potential,” “plan,” “forecasts,” “goal,” “seek,” “intend,” other forms of these words or similar words or expressions or the negative thereof (although not all forward-looking statements contain these words).

We have based our forward-looking statements on our current expectations and projections about trends affecting our business and industry and other future events. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forward-looking statements are subject to substantial risks and uncertainties that could cause our future business, financial condition, results of operations or performance, to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this Report. For instance, if we fail to develop and commercialize diagnostic products, we may be unable to execute our plan of operations. Other risks and uncertainties include those associated with the COVID-19 pandemic; our failure to obtain necessary regulatory clearances or approvals to distribute and market future products in the veterinary or clinical in-vitro diagnostics, or IVD, market; a failure by the marketplace to accept the products in our development pipeline or any other diagnostic products we might develop; our failure to secure adequate intellectual property protection; we will face fierce competition and our intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; and other risks identified elsewhere in this Report, as well as in our other filings with the Securities and Exchange Commission, or the SEC. In addition, actual results may differ as a result of additional risks and uncertainties of which we are currently unaware or which we do not currently view as material to our business. For these reasons, readers are cautioned not to place undue reliance on any forward-looking statements.

You should read this Report in its entirety, together with our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC on February 20, 2020, or our Annual Report, the documents that we file as exhibits to this Report and the documents that we incorporate by reference into this Report, with the understanding that our future results may be materially different from what we currently expect. The forward-looking statements we make speak only as of the date on which they are made. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations. If we do update or correct any forward-looking statements, readers should not conclude that we will make additional updates or corrections.

~~Company Overview~~

The following discussion and analysis of our financial condition and results of operations should be read together with our Unaudited Condensed Consolidated Financial Statements and the related notes included elsewhere in ~~conjunction~~this Report and in our Annual Report. This discussion and analysis contains forward-looking statements that are based on our current expectations and reflect our plans, estimates and anticipated future financial performance. These statements involve numerous risks and uncertainties, including those related to the anticipated impact on our business from, and our response to, the COVID-19 pandemic. Our actual results may differ materially from those expressed or implied by these forward-looking statements as a result of many factors, including those set forth in the section entitled "Risk Factors" in this Report and in our Annual Report, as well as our other public filings with the ~~interim consolidated financial statements and related condensed notes thereto, which are included in Part I~~SEC. Please refer to the section of this ~~Report.~~Report entitled "Cautionary Note Regarding Forward-Looking Statements" for additional information.

Company Overview

VolitionRx is a multi-national epigenetics company that applies its Nucleosomics^TM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and some other ~~diseases.~~ diseases, including sepsis and COVID-19, that are associated with the presence in the blood of networks of fibers released from activated neutrophils, a phenomenon known as NETosis. We hope that through earlier diagnosis we can help save and improve the quality of human and animals' lives throughout the world.

Our ~~tests~~assays are based on the science of Nucleosomics^TM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid, - since changes in these parameters are an indication that disease is present.

~~Our~~Volition's approach is to investigate the epigenetic structure of chromatin and nucleosomes rather than investigating only the DNA sequence. We are continuously developing new technologies including:

`·`~~A suite of low cost Nu.Q~~^TM ~~immunoassays that can accurately measure nucleosomes containing numerous epigenetic signals or structure.~~	·	A suite of low cost Nu.Q® immunoassays that can accurately measure nucleosomes containing numerous epigenetic signals or structures, now being developed on a range of different enzyme-linked immunosorbent assay, or ELISA, platforms.
	·	Nu.Q® Capture technology to isolate or enrich nucleosomes containing particular epigenetic signals or structures for a wide range of potential scientific and medical applications, e.g., the enrichment of nucleosomes of tumor origin in blood samples taken from cancer patients.
	·	The production of synthetic (recombinant) nucleosomes, containing exact defined epigenetic signals and structures, which is now in-house. These nucleosomes are used to ensure maximal accuracy of Nu.Q® immunoassay tests but also have many other applications including Research Use Only, or RUO, kits and as tools in epigenetic drug development.

·~~Nu.Q~~^TM Capture technology to isolate or enrich nucleosomes containing particular epigenetic signals or structures for a wide range of potential scientific and medical applications, such as the enrichment of nucleosomes of tumor origin in blood samples taken from cancer patients.

·~~We plan to develop an ability to produce synthetic (recombinant) nucleosomes containing exact defined epigenetic signals and structures. These are used to ensure exquisite accuracy of Nu.Q~~^TM ~~immunoassay tests but~~Volition has also ~~have many other applications including as tools in epigenetic drug development.~~

~~In addition to human diagnostics we are also developing~~developed the use of the Nu.Q^TM® technology in veterinary ~~applications. An initial proof~~applications and launched its first product, the Nu.Q^® Vet Cancer Screening Test, in the fourth quarter of ~~concept study demonstrated that nucleosomes can be detected~~2020. We are in ~~dogs~~the process of developing additional veterinary products, including a treatment monitoring test, a disease recurrence test and ~~therefore, have the potential to differentiate cancer from other diseases. We will now test Nu.Q~~^TM ~~platform in larger trials in veterinary medicine.~~a point-of-care platform. Our extensive intellectual property portfolio includes the coverage of veterinary applications.

Commercialization Strategy

Volition believes that given the global prevalence of cancer and diseases associated with NETosis, and the low-cost, accessible and routine nature of our tests, Nu.Q^®could potentially be used throughout the world. We plan to work with partners to commercialize Nu.Q^®worldwide.

Commercialization will take multiple forms in various markets and opportunities including, but not limited to:

	·	Licensing and direct sales of the Nu.Q® Vet Cancer Screening Test.
	·	Sales of veterinary clinical products utilizing Nu.Q® Vet assays and/or Nu.Q® Capture reagents through distributor networks.
	·	Licensing of intellectual property, or IP, for clinical products utilizing Nu.Q® assays and/or Nu.Q® Capture reagents.
	·	Sales of clinical products utilizing Nu.Q® assays and/or Nu.Q® Capture reagents through distributor networks.
	·	Licensing of IP for RUO kit sales of Nu.Q® assays and/or Nu.Q® Capture reagents.
	·	Licensing of IP for laboratory developed patient testing services utilizing Nu.Q® assays and/or Nu.Q® Capture reagents.
	·	Provision of direct research services in the processing of samples using Nu.Q® RUO assays and/or Nu.Q® Capture.

Table of Contents

Developments - COVID-19 Pandemic

On March 11, 2020, the World Health Organization designated the outbreak of the novel strain of coronavirus known as COVID-19 as a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work. Uncertainty with respect to the economic effects of the pandemic has introduced significant volatility in the financial markets.

~~During~~Throughout 2020 and the first six months of ~~2020,~~2021, we have implemented contingency planning to protect the health and well-being of our employees, with ~~most~~the majority of our employees working remotely where possible. We have implemented travel restrictions as well as protocols limiting visitor ~~protocols~~access to our facilities, and we are following social distancing practices. ~~We did not observe significant impacts on~~

As a result of the COVID-19 pandemic, we have experienced and may continue to experience disruptions that could impact our clinical trials, including:

	·	delays in enrolling patients in clinical trials;
	·	delays in sample collection; and
	·	diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as clinical trial sites and hospital staff supporting the conduct of our clinical trials.

The extent to which the COVID-19 pandemic will impact our business, orfinancial condition, and results of operations ~~for~~in the ~~quarter ended June 30, 2020 due to~~future is highly uncertain and will be affected by a number of factors. These include the ~~global emergence~~duration and extent of the COVID-19 pandemic, the development of new variants of the COVID-19 virus that may be more contagious or virulent than previous versions, the scope of mandated or recommended containment and mitigation ~~actions taken to slow its spread. To~~measures, the ~~extent~~effect of government stabilization and recovery efforts, and the pandemic worsens, we cannot predict the effects it may have on our business, in particular with respect to demand for our services, our strategy, and our prospects, or the impact on our financial results.success of vaccine distribution programs.

~~Plan of Operations~~

We have identified the specific processes and resources required to achieve the near and medium-term objectives of our business plan, including personnel, facilities, equipment, research and testing materials including antibodies and clinical samples, and the protection of intellectual property. To date, operations have proceeded satisfactorily in relation to our business plan. However, it is possible that some resources will not readily become available in a suitable form or on a timely basis or at an acceptable cost. It is also possible that the results of some processes may not be as expected, and that modifications of procedures and materials may be required. Such events could result in delays to the achievement of the near and medium-term objectives of our business plan, in particular the progression of clinical validation studies and regulatory approval processes for the purpose of bringing products to the IVD and veterinary markets.

Our future as an operating business will depend on our ability to obtain sufficient capital contributions, financing and/or generate revenues as may be required to sustain our operations. Management plans to address the above as needed by: (a) securing additional grant funds; (b) obtaining additional equity or debt financing; (c) granting licenses to third parties in exchange for specified up-front and/or back-end payments; and (d) developing and commercializing our products on an accelerated timeline. Management continues to exercise tight cost controls to conserve cash.

Our ability to continue as a going concern is dependent upon our accomplishment of the plans described in the preceding paragraph and eventually to attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. If we are unable to obtain adequate capital, we could be forced to cease operations.

Liquidity and Capital Resources

We have financed our operations since inception primarily through private placements and public offerings of our common stock. As of June 30, ~~2020,~~2021, we had cash and cash equivalents of approximately ~~$21.3~~$27.9 million.

Net cash used in operating activities was ~~$9.2~~$11.6 million and ~~$6.4~~$9.2 million for the six months ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively. The increase in cash used in operating activities for the period ended June 30, ~~2020~~2021 when compared to same period in ~~2019~~2020 was primarily due to increased ~~expenditures on antibodies, sample purchases, stage payment~~payroll costs reflecting growth in staff numbers, higher legal and professional fees in relation to ~~a collaborator partner~~the registered public offering and ~~common stock issued for services.~~an increase in marketing expenses.

Net cash used in investing activities was ~~$0.6~~$0.7 million and ~~$0.2~~$0.6 million for the six months ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively. The increase was primarily due to purchases of laboratory equipment.

Net cash provided by financing activities was ~~$13.9~~$20.7 million and ~~$11.8~~$13.9 million for the six months ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively. The increase in cash provided by financing activities for the period ended June 30, ~~2020~~2021 when compared to same period in ~~2019~~2020 was primarily due to $18.9 million in net cash received from the issuance of shares of common stock in a registered public offering in February 2021, $1.2 million in cash received from the issuance of shares of common stock pursuant to the 2018 Equity Distribution Agreement and $1.2 million in cash received from the issuance of shares of common stock pursuant to the 2020 Equity Distribution Agreement, compared to $12.7 million in net cash received from the issuance of shares of common stock in a registered public offering in May 2020 and $1.7 million in cash received from the issuance of shares of common stock pursuant to the 2018 Equity Distribution Agreement. For additional information on the "at the market offering program," refer to Note 6, Common Stock - Equity Distribution Agreements, of the Notes to Condensed Consolidated Financial Statements.

Table of Contents

The following table summarizes our approximate contractual payments due by year as of June 30, ~~2020.~~2021.

~~Approximate Payments (Including Interest) Due by Year~~

Approximate Payments (Including Interest) Due by Year

	Total		2021 (Remaining)		2022 - 2025		2026 +
Description	$		$		$		$
Finance Lease Obligations		699,740		36,917		256,467		406,356
Operating Lease Obligations		413,717		141,985		271,732		-
Grants Repayable		308,692		-		130,952		177,740
Long-Term Debt		3,424,381		508,394		2,131,087		784,900
Collaborative Agreements Obligations		964,099		842,026		122,073		-
Total		5,810,629		1,529,322		2,912,311		1,368,996

Total

2020 (Remaining)

2021 - 2024

2025 +
Description

$

$

$

$
Finance Lease Obligations

733,316

34,997

252,685

445,634
Operating Lease Obligations

251,814

121,708

130,106

-
Grants Repayable

341,427

52,915

166,158

122,354
Long-Term Debt

2,881,069

479,678

2,221,014

180,377
Collaborative Agreements Obligations

2,392,158

1,098,624

1,293,534

-
Total

6,599,784

1,787,922

4,063,497

748,365

We intend to use our cash reserves to predominantly fund further research and development activities. We do not currently have any substantial source of revenues and expect to rely on additional future financing, through the sale of equity or debt securities, or the sale of licensing rights, to provide sufficient funding to execute our strategic plan. There is no assurance that we will be successful in raising further funds.

In the event that additional financing is delayed, we will prioritize the maintenance of our research and development personnel and facilities, primarily in Belgium, and the maintenance of our patent rights. In such instance, the completion of clinical validation studies and regulatory approval processes for the purpose of bringing products to the IVD and veterinary ~~market~~markets would be delayed. In the event of an ongoing lack of financing, it may be necessary to discontinue operations, which will adversely affect the value of our common stock.

We have not attained profitable operations and are dependent upon obtaining financing to pursue any extensive activities. For these reasons, our auditors stated in their report on our audited financial statements for the ~~fiscal~~ year ended December 31, ~~2019~~2020 an explanatory paragraph regarding factors that raise substantial doubt that we will be able to continue as a going concern.

Table of Contents

Results of Operations

Comparison of the Three Months Ended June 30, ~~2020~~2021 and June 30, ~~2019~~2020

The following table sets forth our results of operations for the three months ended on June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively:

				Percentage
	Three Months ended June 30,		Increase	Increase		Three Months Ended June 30,				Increase		Increase
	2020	2019	(Decrease)		(Decrease)	2021		2020		(Decrease)		(Decrease)
	$	$	$		%	$		$		$		%

Royalty	1,872	-	1,872		100%		-		1,872		(1,872)	(100%)
Product	3,322	-	3,322		100%		24,782		3,322		21,460		>100%
Total Revenues	5,194	-	5,194		100%		24,782		5,194		19,588		>100%

Research and development	3,492,845	2,478,930	1,013,915		41%		3,649,469		3,492,845		156,624		4%
General and administrative	1,508,836	1,436,461	72,375		5%		1,816,599		1,508,836		307,763		20%
Sales and marketing	215,891	238,124	(22,233)		(9%)		459,371		215,891		243,480		>100%

Total Operating Expenses	5,217,572	4,153,515	1,064,057		26%		5,925,439		5,217,572		707,867		14%

Grant income	90,946	-	90,946		100%		391,532		90,946		300,586		>100%
Gain on disposal of fixed assets	93,202	-	93,202		100%
(Loss) Gain on disposal of fixed assets							(26,166)		93,202		(119,368)	(100%)
Interest income	7,741	29,459	(21,718)		(74%)		492		7,741		(7,249)	(94%)
Interest expense	(22,604)	(33,115)	(10,511)		(32%)		(39,688)		(22,604)		17,084		76%
Total Other Income							326,170		169,285		156,885		93%

Total Other Income (Expenses)	169,285	(3,656)	(172,941)		(>100%)
Net Loss	(5,043,093)	(4,157,171)	885,922		21%		(5,574,487)		(5,043,093)		531,394		11%

Revenues

Our operations are still predominantly in the research and development stage and we had limited revenues of ~~$5,194~~$24,782 and ~~$nil~~$5,194 during the three months ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively. The main source of revenues during the three months ended June 30, 2021 was direct sales of the Nu.Q^®Vet Cancer Screening Test via the Gastrointestinal Laboratory at Texas A&M University.

Operating Expenses

Total operating expenses increased to $5.9 million from $5.2 million ~~from $4.2 million for~~during the three months ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively, as a result of the factors described below.

Table of Contents

Research and Development Expenses

Research and development expenses increased to ~~$3.5 million from $2.5~~$3.6 million for the three months ended June 30, ~~2020 and~~2021 from $3.5 million for the three months ended June 30, ~~2019, respectively.~~2020. This increase ~~in overall research and development expenditures~~ was primarily related to higher ~~antibody costs, sample costs, laboratory expenses and~~ personnel expenses offset by lower research and collaboration costs during the period.

	Three Months ended June 30,			Three Months Ended June 30,
	2020	2019	Change	2021		2020		Change
	$	$	$	$		$		$
Personnel expenses	1,212,777	932,333	280,444		1,536,490		1,212,777		323,713
Stock-based compensation	114,872	104,055	10,817		25,347		114,872		(89,525)
Direct research and development expenses	1,936,125	1,208,742	727,383		1,664,941		1,936,125		(271,184)
Other research and development	(50,770)	59,480	(110,250)		161,830		(50,770)		212,600
Depreciation and amortization	279,841	174,320	105,521		260,861		279,841		(18,980)
Total research and development expenses	3,492,845	2,478,930	1,013,915		3,649,469		3,492,845		156,624

General and Administrative Expenses

General and administrative expenses increased to ~~$1.5~~$1.8 million from ~~$1.4~~$1.5 million for the three months ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively. This increase was primarily due to higher ~~legal and professional fees offset by lower travel costs~~personnel expenses during the period.

	Three Months ended June 30,			Three Months Ended June 30,
	2020	2019	Change	2021		2020		Change
	$	$	$	$		$		$
Personnel expenses	511,652	565,657	(54,005)		776,911		511,652		265,259
Stock-based compensation	204,055	235,701	(31,646)		240,855		204,055		36,800
Legal and professional fees	507,732	321,859	185,873		490,777		507,732		(16,955)
Other general and administrative	230,146	301,500	(71,354)		275,499		230,146		45,353
Depreciation and amortization	55,251	11,744	43,507		32,557		55,251		(22,694)
Total general and administrative expenses	1,508,836	1,436,461	72,375		1,816,599		1,508,836		307,763

Sales and Marketing Expenses

Sales and marketing expenses ~~were at the same level of~~increased to $0.5 million from $0.2 million for the three months ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively. ~~There~~This increase was ~~an increase in~~primarily due to higher personnel expenses during the period and direct marketing and professional ~~fees offset by lower travel and personnel costs during the period.~~fees.

	Three Months ended June 30,			Three Months Ended June 30,
	2020	2019	Change	2021			2020		Change
	$	$	$	$			$		$
Personnel expenses	110,753	169,945	(59,192)		231,082			110,753		120,329
Stock-based compensation	41,713	39,877	1,836		71,542	��		41,713		29,829
Direct marketing and professional fees	63,425	28,302	35,123		156,747			63,425		93,322
Total sales and marketing expenses	215,891	238,124	(22,233)		459,371			215,891		243,480

Other Income ~~(Expenses)~~

For the three months ended June 30, ~~2020,~~2021, the ~~Company’s~~Company's other income was ~~$169,285~~$326,170 compared to other ~~expenses~~income of ~~$3,656,~~$169,285 for the three months ended June 30, ~~2019.~~2020. The increase in other income was mainly due to grant ~~income received and a gain on disposal of a fixed asset, offset by less interest received from cash deposited in an overnight money market deposit account.~~income.

Net Loss

For the three months ended June 30, ~~2020,~~2021, the ~~Company’s~~Company's net loss was ~~$5.0~~$5.6 million ~~compared~~in comparison to a net loss of ~~$4.2~~$5.0 million for the three months ended June 30, ~~2019.~~2020. The change was primarily a result of the factors described above.

Table of Contents

Comparison of the Six Months Ended June 30, ~~2020~~2021 and June 30, ~~2019~~2020

The following table sets forth our results of operations for the six months ended on June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively:

				Percentage
	Six Months Ended June 30,		Increase	Increase
	2020	2019	(Decrease)	(Decrease)	Six Months Ended June 30,				Increase		Percentage Increase
	$	$	$	%	2021		2020		(Decrease)		(Decrease)
					$		$		$		$
Royalty	2,112	-	2,112	100%		-		2,112		(2,112)		(100)%
Product	3,626	-	3,626	100%		50,312		3,626		46,686		>100%
Total Revenues	5,738	-	5,738	100%		50,312		5,738		44,574		>100%

Research and development	7,387,811	4,953,489	2,434,322	49%		7,522,547		7,387,811		134,736		2%
General and administrative	3,212,358	2,665,901	546,457	20%		3,626,759		3,212,358		414,401		13%
Sales and marketing	489,845	522,404	(32,559)	(6%)		886,772		489,845		396,927		81%

Total Operating Expenses	11,090,014	8,141,794	2,948,220	36%		12,036,078		11,090,014		946,064		9%

Grant income	98,870	-	98,870	100%		391,532		98,870		292,662		>100%
Gain on disposal of fixed assets	93,202	-	93,202	100%
(Loss) / Gain on disposal of fixed assets						(26,167)		93,202		(119,369)		(100)%
Interest income	46,155	41,023	5,132	13%		2,213		46,155		(43,942)		(95)%
Interest expense	(56,383)	(63,216)	6,833	(11%)		(81,869)		(56,383)		25,486		45%
Other expenses	-	(196,957)	196,957	(100%)

Total Other Income (Expenses)	181,844	(219,150)	400,994	(183%)
Total Other Income						285,709		181,844		103,865		57%

Net Loss	(10,902,432)	(8,360,944)	2,541,488	30%		(11,700,057)		(10,902,432)		797,625		7%

Revenues

Our operations are still predominantly in the research and development stage and we had limited revenues of ~~$5,738~~$50,312 and ~~$nil~~$5,738 during the six months ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively. The main source of revenues during the six months ended June 30, 2021 was direct sales of the Nu.Q^®Vet Cancer Screening Test via the Gastrointestinal Laboratory at Texas A&M University.

Operating Expenses

Total operating expenses increased to ~~$11.1~~$12.0 million from ~~$8.1~~$11.1 million for the six months ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively as a result of the factors described below.

Table of Contents

Research and Development Expenses

Research and development expenses increased to $7.5 million for the six months ended June 30, 2021, from $7.4 million for the six months ended June 30, ~~2020, from $5.0 million for the six months ended June 30, 2019.~~2020. This increase in overall research and development expenditures was primarily related to ~~higher antibody costs, higher sample costs, laboratory expenses,~~increased personnel expenses offset by lower antibody and ~~management compensation connected to Volition Germany~~research and collaboration costs during the period.

	Six Months Ended June 30,			Six Months Ended June 30,
	2020	2019	Change	2021		2020		Change
	$	$	$	$		$		$
Personnel expenses	2,506,925	1,864,322	642,603		3,028,929		2,506,925		522,004
Stock-based compensation	177,291	199,046	(21,755)		115,474		177,291		(61,817)
Direct research and development expenses	3,364,563	2,222,030	1,142,533		3,243,601		3,364,563		(120,962)
Other research and development	966,105	323,153	642,952		627,810		966,105		(338,295)
Depreciation and amortization	372,927	344,938	27,989		506,733		372,927		133,806
Total research and development expenses	7,387,811	4,953,489	2,434,322		7,522,547		7,387,811		134,736

General and Administrative Expenses

General and administrative expenses increased to ~~$3.2~~$3.6 million from ~~$2.7~~$3.2 million for the six months ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively. This increase was primarily due to higher personnel expenses and legal fees ~~and foreign exchange costs, offset by lower stock–based compensation charges~~ during the period.

	Six Months Ended June 30,			Six Months Ended June 30,
	2020	2019	Change	2021		2020		Change
	$	$	$	$		$		$
Personnel expenses	1,040,831	1,181,261	(140,430)		1,393,982		1,040,831		353,151
Stock-based compensation	311,320	430,765	(119,445)		574,721		311,320		263,401
Legal and professional fees	927,589	631,317	296,272		1,055,435		927,589		127,846
Other general and administrative	820,441	401,587	418,854		538,546		820,441		(281,895)
Depreciation and amortization	112,177	20,971	91,206		64,075		112,177		(48,102)
Total general and administrative expenses	3,212,358	2,665,901	546,457		3,626,759		3,212,358		414,401

Sales and Marketing Expenses

Sales and marketing expenses ~~were at the same level of~~increased to $0.9 million from $0.5 million for the six months ended June 30, ~~2020~~2021 and June 30, ~~2019,~~2020, respectively. ~~There~~This increase was ~~an increase in~~primarily due to higher personnel expenses and direct marketing and professional fees ~~offset by lower stock-based compensation costs and travel costs~~ during the period.

	Six Months Ended June 30,			Six Months Ended June 30,
	2020	2019	Change	2021		2020		Change
	$	$	$	$		$		$
Personnel expenses	261,698	327,784	(66,086)		415,219		261,698		153,521
Stock-based compensation	64,698	90,280	(25,582)		202,891		64,698		138,193
Direct marketing and professional fees	163,449	104,340	59,109		268,662		163,449		105,213
Total sales and marketing expenses	489,845	522,404	(32,559)		886,772		489,845		396,927

Other Income ~~(Expenses)~~

For the six months ended June 30, ~~2020,~~2021, the ~~Company’s~~Company's other income was ~~$181,844~~$285,709 compared to other ~~expenses~~income of ~~$219,150~~$181,844 for the six months ended June 30, ~~2019.~~2020. This increase in other income was primarily due to grant income received, interest received from cash deposited in an overnight money market deposit account, and a gain on disposal of a fixed asset, offset by other expenses related to the amendment to outstanding warrants which resulted in a $196,957 expense in the same period in 2019.income.

Table of Contents

Net Loss

For the six months ended June 30, ~~2020,~~2021, the ~~Company’s~~Company's net loss was ~~$10.9~~$11.7 million ~~an increase of approximately $2.5 million, or 30%,~~ in comparison to a net loss of ~~$8.4~~$10.9 million for the six months ended June 30, ~~2019.~~2020. The change was a result of the factors described above.

Going Concern

We have not attained profitable operations and are dependent upon obtaining external financing to continue to pursue our operational and strategic plans. For these reasons, management has determined that there is substantial doubt that the business will be able to continue as a going concern without further financing.

Off-Balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to stockholders.

Future Financings

We may seek to obtain additional capital through the sale of debt or equity securities, if we deem it desirable or necessary. These sales may include the sale of equity securities from time to time through our "at the market offering program" with Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc. under the Equity Distribution Agreement dated November 10, 2020 (see Note 6 of the notes to the condensed consolidated financial statements). However, we may be unable to obtain such additional capital when needed, or on terms favorable to us or our stockholders, if at all. If we raise additional funds by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution, or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. If additional funds are raised through the issuance of debt securities, the terms of such securities may place restrictions on our ability to operate our business.

Critical Accounting Policies

Our interim consolidated financial statements and ~~accompanying~~related condensed notes have been prepared in accordance with United States generally accepted accounting principles, or U.S. GAAP, applied on a consistent basis. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. A ~~complete~~ summary of these policies is included in the notes to our financial statements. In general, management's estimates are based on current facts, historical ~~experience, on~~experiences, information from third party professionals and on various other ~~assumptions~~factors that ~~are believed~~it believes to be reasonable under the ~~facts and~~ circumstances. Actual results could differ materially and adversely from those estimates made by management. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected.

Recently Issued Accounting Pronouncements

The Company has implemented all applicable new accounting pronouncements that are in effect. The Company does not believe that there are any other applicable new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company ~~as defined by Rule 12b-2 of the Exchange Act~~ and are not required to ~~provide the information under~~disclose this ~~item.~~information.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

Disclosure controls and procedures are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by our company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including our Principal Executive and Principal Financial Officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Our management carried out an evaluation, under the supervision and with the participation of our Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures ~~pursuant to~~(as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange ~~Act.~~Act). Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer have concluded, as they previously concluded as of December 31, ~~2019,~~2020, that our disclosure controls and procedures ~~continue to~~were not be effective as of June 30, ~~2020,~~2021, because of material weaknesses in our internal control over financial reporting, as ~~described~~referenced below and described in detail in our Annual ~~Report.~~Report for the year ended December 31, 2020.

~~Changes~~A material weakness is a deficiency, or a combination of deficiencies, in ~~Internal Control~~internal control over ~~Financial Reporting~~financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

The ~~Audit Committee of~~deficiencies identified involve the Board of Directors meets regularly with our financial management, and with the independent registered public accounting firm engaged by us. Internal accounting controls and the quality of financial reporting are discussed during these meetings. The Audit Committee has discussed with the independent registered public accounting firm matters required to be discussed by the auditing standards adopted or established by the Public Company Accounting Oversight Board (“PCAOB”). In addition, the Audit Committee and the independent registered public accounting firm have discussed the independent registered public accounting firm’s independence from the Company and its management, including the matters in the written disclosures required by PCAOB Rule 3526 “~~Communicating with Audit Committees Concerning Independence~~.”

~~As of June 30, 2020, we did not maintain sufficient internal controls over financial reporting due to insufficient:~~

·segregation of duties in some areas of ~~Finance;~~

·finance, the oversight in ~~the area of Information Technology,~~information technologies, where certain processes may affect the internal controls over financial ~~reporting;~~reporting, and

·the monitoring of review controls with respect to accounting for complex transactions.

During the first half of 2021, our management, with oversight from our audit committee, has implemented the following remediation steps to help address and mitigate some of the underlying deficiencies which gave rise to the previously disclosed material weaknesses and to improve our internal control over financial reporting:

	·	hired additional full-time accounting resources and financial planning and analysis resources with appropriate levels of experience;
	·	changed certain organizational reporting lines and reallocated certain responsibilities to improve segregation of duties; and
	·	reallocated responsibilities across the finance and accounting organization to ensure that the appropriate level of knowledge and experience is applied based on complexity of tasks being undertaken.

We ~~have developed, and are currently implementing, a remediation plan for these material weaknesses. Specifically, we have implemented a financial reporting system that has allowed further automation of~~intend to take additional steps to mitigate the ~~reporting process, thereby strengthening the control environment over financial reporting.~~ issues identified. Such measures include but may not be limited to:

	·	strengthening our internal processes and reviews, including formal documentation thereof;
	·	preparation of risk-control matrices to identify key risks and develop and document policies to mitigate those risks; and
	·	engaging additional resources if necessary to help us assess, document, design and implement control activities related to internal control over financial reporting.

As we continue to evaluate and ~~work~~test the remediation plan outlined above, we may also identify additional measures to ~~enhance~~address the material weaknesses or modify certain of the remediation procedures described above. We also may implement additional changes to our internal control over financial reporting as may be appropriate in the course of remediating the material weakness. Management, with the oversight of our audit committee, will continue to take steps necessary to remedy the material weakness to reinforce the overall design and capability of our control environment.

Changes in Internal Control over Financial Reporting

Except for the ongoing remediation of the material weaknesses in internal controls over financial reporting ~~we may determine that additional measures should be taken to address these or other control deficiencies, and/or that we should modify our remediation plan considering the Company’s size and growth.~~

~~There have been~~noted above, no changes in our internal ~~controls~~control over financial reporting ~~that occurred~~were made during the fiscal quarter ended June 30, ~~2020, other than those described above,~~2021, that have materially affected, or are reasonably likely to materially affect, our internal ~~controls~~control over financial reporting.

Once the Company is engaged in stable business operations and has sufficient personnel and resources available, then our Board of Directors, in particular and in connection with the aforementioned deficiencies, will establish the following remediation measures:

·~~Additional Finance resources will be recruited to resolve the segregation of duties control weaknesses noted above;~~

·~~Internal audit resources will be contracted to review and advise on control weaknesses across the organization; and~~

·Specialist resources in IT and Human Resources will be recruited to recommend and implement relevant policy and processes to strengthen IT and Human Resources internal controls associated with financial reporting.

Limitations of the Effectiveness of Disclosure Controls and Internal Controls

Our management, including our Principal Executive Officer and Principal Financial Officer, does not expect that our disclosure controls and internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control.

The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions; over time, a control may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

~~PART~~

Table of Contents

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

In the ordinary course of business, we may be subject to claims, counter claims, lawsuits and other litigation of the type that generally arise from the conduct of our business. We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our directors, officers or any affiliates, or any registered or beneficial stockholders, is an adverse party or has a material interest adverse to our interest.

ITEM 1A.RISK FACTORS

There have been no material changes in our assessment of risk factors affecting our business since those presented in Part I, Item 1A of our Annual ~~Report, as supplemented in Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.~~Report.

ITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Recent Sales of Unregistered Securities

None.

Repurchase of Equity Securities

No equity securities were repurchased during the second quarter of 2021.

ITEM 3.DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.OTHER INFORMATION

None.

Table of Contents

ITEM 6. EXHIBITS

Incorporated by Reference

Exhibit
Number

Exhibit Description

Form

File No.

Exhibit

Filing Date

Filed
Herewith

10.1

Underwriting Agreement, dated May 20, 2020, between the Company and National Securities Corporation, as representative of the several Underwriters named therein.

8-K

001-36833

1.1

5/22/20

31.1

Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.

X

31.2

Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.

X

32.1*

Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

X

101.INS

XBRL Instance Document.

X

101.SCH

XBRL Taxonomy Extension Schema Document.

X

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document.

X

101.LAB

XBRL Taxonomy Extension Label Linkbase Document.

X

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document.

X

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document.

X

Incorporated by Reference

Exhibit Number

Exhibit Description

Form

File No.

Exhibit

Filing Date

Filed

Herewith

10.1#

2015 Stock Incentive Plan, as amended

8-K

001-36833

10.1

06/22/21

10.2#†

Consulting Services Agreement by and between Volition Germany and 3F Management SPRL (Gaetan Michel), dated January 29, 2021; First Amendment dated February 1, 2021; Second Amendment dated May 1, 2021.

10-Q

001-36833

10.7

05/11/21

31.1

Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.

31.2

Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.

32.1*

Certifications of Chief Executive Officer and Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS

XBRL Instance Document.

101.SCH

XBRL Taxonomy Extension Schema Document.

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document.

101.LAB

XBRL Taxonomy Extension Label Linkbase Document.

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document.

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document.

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

# Indicates a management contract or compensatory plan or arrangement.

† Portions of this exhibit are redacted pursuant to Item 601(a)(6) and/or Item (b)(10)(iv) under Regulation S-K. The registrant agrees to furnish supplementally any omitted schedules to the SEC upon request.

*The certifications attached as Exhibit 32.1 accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed ~~“filed”~~"filed" by the registrant for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any of the ~~registrant’s~~registrant's filings under the Securities Act or the Exchange Act, irrespective of any general incorporation language contained in any such ~~filing~~ filing.

~~SIGNATURES~~

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	VOLITIONRX LIMITED
	~~VOLITIONRX LIMITED~~
Dated: August 11, 2021	By:	/s/ Cameron Reynolds
		Cameron Reynolds

~~Dated: August 13, 2020~~		~~By:~~ ~~/s/ Cameron Reynolds~~
			~~Cameron Reynolds~~
			President and Chief Executive Officer (Authorized Signatory and Principal Executive Officer)

Dated: August 11, 2021		/s/ Terig Hughes
		Terig Hughes
~~Dated: August 13, 2020~~		~~By:~~ ~~/s/ David Vanston~~
			~~David Vanston~~
			Chief Financial Officer and Treasurer (Authorized Signatory and Principal ~~Financial~~ Financial and Accounting Officer)

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to _____

				Accumulated
			Additional	Other			Non
	Common Stock		Paid-in	Comprehensive	Accumulated		Controlling
	Shares	Amount	Capital	Income (Loss)	Deficit		Interest	Total
	#	$	$	$	$		$	$
Balance, December 31, 2019	41,125,303	41,125	103,853,627	125,670	(89,821,856)		-	14,198,566

Common stock issued for Director compensation in Volition Germany	73,263	73	333,896	-	-		-	333,969
Common stock issued for cashless exercise of stock options	19,430	20	(20)	-	-		-	-
Stock-based compensation		-	192,669	-	-		-	192,669
Stock repurchase	(11,364)	(11)	(54,423)	-	-		-	(54,434)
Foreign currency translation	-	-	-	373,926	-		-	373,926
Net loss for the period	-	-	-	-	(5,849,772)		(9,567)	(5,859,339)
Balance, March 31, 2020	41,206,632	41,207	104,325,749	499,596	(95,671,628)		(9,567)	9,185,357
Common stock issued for cash, net	5,452,922	5,453	14,229,160	-	-		-	14,234,613
Stock-based compensation	-	-	360,640	-	-		-	360,640
Foreign currency translation	-	-	-	(74,320)	-		-	(74,320)
Net loss for the period	-	-	-	-	(5,037,314)		(5,779)	(5,043,093)
Balance, June 30, 2020	46,659,554	46,660	118,915,549	425,276		(100,708,942)	(15,346)	18,663,197

		Weighted
	Number of	Average
	Warrants	Exercise Price ($)
Outstanding at December 31, 2019	190,000	2.90
Granted	50,000	3.45
Exercised	-	-
Expired	-	-
Outstanding at June 30, 2020	240,000	3.02

Exercisable at June 30, 2020	190,000	2.90

			Weighted
			Average
			Remaining	Proceeds to
Number	Number	Exercise	Contractual	Company if
Outstanding	Exercisable	Price ($)	Life (Years)	Exercised ($)
150,000	150,000	2.47	1.44	370,500
50,000	-	3.45	5.67	172,500
40,000	40,000	4.53	0.38	181,200
240,000	190,000			724,200

	Number of	Weighted Average
	Options	Exercise Price ($)
Outstanding at December 31, 2019	4,169,301	3.88
Granted	835,000	3.60
Exercised	(68,882)	3.33
Expired/Cancelled	(19,167)	5.00
Outstanding at June 30, 2020	4,916,252	3.84

Exercisable at June 30, 2020	4,081,252	3.89

2020 - remaining	$	121,708
2021	$	77,664
2022	$	34,500
2023	$	16,886
2024	$	1,056
Total Operating Lease Obligations	$	251,814
Less: Amount representing interest	$	(9,803)
Present Value of minimum lease payments	$	242,011

2020 - remaining	$	1,740
Total Operating Lease Obligations	$	1,740

2020 - remaining	$	1,098,624
2021 - 2024	$	1,293,534
Total Collaborative Agreement Obligations	$	2,392,158

	Total	2020 (Remaining)	2021 - 2024	2025 +
Description	$	$	$	$
Finance Lease Obligations	733,316	34,997	252,685	445,634
Operating Lease Obligations	251,814	121,708	130,106	-
Grants Repayable	341,427	52,915	166,158	122,354
Long-Term Debt	2,881,069	479,678	2,221,014	180,377
Collaborative Agreements Obligations	2,392,158	1,098,624	1,293,534	-
Total	6,599,784	1,787,922	4,063,497	748,365